Use of stable isotope labelling to study protein degradation in chick embryonic skeletal muscle cell cultures by Fuller, John C., Jr.
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
1991
Use of stable isotope labelling to study protein
degradation in chick embryonic skeletal muscle cell
cultures
John C. Fuller Jr.
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Agriculture Commons, and the Animal Sciences Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Fuller, John C. Jr., "Use of stable isotope labelling to study protein degradation in chick embryonic skeletal muscle cell cultures "
(1991). Retrospective Theses and Dissertations. 10032.
https://lib.dr.iastate.edu/rtd/10032
INFORMATION TO USERS 
This manuscript has been reproduced from the microfîhn master. UMI 
films the text directly from the original or copy submitted. Thus, some 
thesis and dissertation copies are in typewriter face, while others may 
be from any type of computer printer. 
The quality of this reproduction is dependent upon the quality of the 
copy submitted. Broken or indistinct print, colored or poor quality 
illustrations and photographs, print bleedthrough, substandard margins, 
and improper alignment can adversely affect reproduction. 
In the unlikely event that the author did not send UMI a complete 
manuscript and there are missing pages, these will be noted. Also, if 
unauthorized copyright material had to be removed, a note will indicate 
the deletion. 
Oversize materials (e.g., maps, drawings, charts) are reproduced by 
sectioning the original, beginning at the upper left-hand corner and 
continuing from left to right in equal sections with small overlaps. Each 
original is also photographed in one exposure and is included in 
reduced form at the back of the book. 
Photographs included in the original manuscript have been reproduced 
xerographically in this copy. Higher quality 6" x 9" black and white 
photographic prints are available for any photographs or illustrations 
appearing in this copy for an additional charge. Contact UMI directly 
to order. 
University Microfilms International 
A Sell & Howell Information Company 
300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA 
313/761-4700 800/521-0600 

Order Number 9202353 
Use of stable isotope labelling to study protein degradation in 
chick embryonic skeletal muscle cell cultures 
Fuller, John C., Jr., Ph.D. 
Iowa State University, 1991 
U M I  
300 N. ZeebRd. 
Ann Arbor, MI 48106 

Use of stable isotope labelling to study protein degradation 
in chick embryonic skeletal muscle cell cultures. 
by 
John C. Fuller, Jr. 
A Dissertation Submitted to the 
Graduate Faculty in Partial Fulfillment of the 
Requirements for the Degree of 
DOCTOR OF PHILOSOPHY 
Department: Animal Science 
Major: Muscle Biology 
APPROVED: 
Members of the Committee: 
In Chargé of Major Work 
F the Major De] lent 
lowa State University 
Ames, Iowa 
1991 
Signature was redacted for privacy.
Signature was redacted for privacy.
Signature was redacted for privacy.
Signature was redacted for privacy.
ii 
TABLE OF CONTENTS 
GENERAL INTRODUCTION 1 
EXPLANATION OF DISSERTATION FORMAT 14 
SECTION I. USE OF A STABLE ISOTOPE METHODOLOGY FOR 
STUDYING THE EFFECTS OF LEUPEPTIN, CALPAIN 
INHIBITOR I, AND CALPAIN INHIBITOR H ON 
PROTEIN TURNOVER IN EMBRYONIC CHICK 
SKELETAL MUSCLE CELL CULTURES 15 
ABSTRACT 17 
INTRODUCTION 19 
MATERL\LS AND METHODS 23 
RESULTS 33 
DISCUSSION 52 
ACKNOWLEDGMENTS 55 
REFERENCES 56 
SECTION n. EFFECT OF CYCLOHEXIMIDE ON PROTEIN 
DEGRADATION IN CHICK SKELETAL MUSCLE CELL 
CULTURES AS DETERMINED BY THE USE OF 
RADIO- AND STABLE-ISOTOPE LABELLED LEUCINE 59 
ABSTRACT 61 
INTRODUCTION 63 
MATERIALS AND METHODS 67 
RESULTS 73 
DISCUSSION 81 
ACKNOWLEDGMENTS 85 
iii 
REFERENCES 86 
SECTION m. DISPARATE RESPONSES OF CULTURED SKELETAL 
MUSCLE CELLS AND GROWING CHICKS TO 
TRIPEPTIDE ALDEHYDE PROTEASE INHIBITORS 
AND AN IN VIVO INTERACTION WITH ETHANOL 89 
ABSTRACT 91 
INTRODUCTION 93 
MATERIALS AND METHODS 95 
RESULTS 101 
DISCUSSION 108 
ACKNOWLEDGMENTS 111 
REFERENCES 112 
GENERAL SUMMARY AND CONCLUSIONS 115 
ACKNOWLEDGEMENTS 119 
RHJERENCES 120 
1 
GENERAL INTRODUCTION 
Our interest is in studying meat animal growth. Since meat animal growth involves 
the production of lean tissue, i.e. muscle, the knowledge of basic muscle protein metabolism 
is important if we are to make the process more efficient. Muscle growth may be defined 
as the relatively small difference between protein synthesis and degradation in the muscle 
tissue. Protein synthesis is a much more costly operation in terms of energetics than protein 
degradation, therefore to decrease the rate of protein degradation would have a greater effect 
in increasing the growth rate than would an increase of protein synthesis^ Genetics, along 
with increased knowledge of nutrition, has played a large role in increasing the growth rate 
of poultry to date. This has mainly been accomplished with an increase in the rate of protein 
synthesis in the animal body.^ Today attention is shifting to the rate of protein degradation. 
Although some amount of protein degradation is probably vitally important to the animal, 
there is probably also a component of general protein degradation that might be reduced. 
This would produce conditions more favorable for growth. Lowering the rate of protein 
degradation a few percent will have great economic significance^'^. 
For some years we have known that the rates of protein synthesis and degradation do 
not remain constant over the life of an animal. It has been demonstrated in lambs, chickens, 
and rats that the rates of both protein synthesis and degradation are highest in the young 
animal at birth or hatching.^ These rates both decline steadily with age, until, in the adult 
animal they are equal. Protein synthesis and degradation are then used for maintaining the 
tissues and maintaining a metabolic balance in the animal. This same trend has been shown 
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in humans, with the additional report that adult males have a protein degradative rate 
approximately 65 % higher than adult females.'^ Though there are general trends, the rates 
of protein degradation between muscles within the same species vary greatly/ For 
example, in most species slow, red type muscles usually have a higher rate of protein 
degradation than faster, white fiber type muscles/ A difference in protein degradation 
between strains of animals within the same species has also been shown. Using tissue 
culture techniques, it has been shown that myosin heavy chain half life varies from 45 h in 
a layer strain to 103 h in a broiler type strain/»^ 
In the cell there are many thousands of proteins, all with specific functions, and 
together they function structurally and enzymatically to make the cell function as a whole. 
Each protein intrinsically has its own half-life, that controls the programmed time that the 
protein functions in the cell. In addition to this preprogrammed degradation, the degradation 
of proteins that have become damaged or are the result of synthetic mistakes must also 
occur. Another purpose for protein degradation in the cell is for remodelling and 
restructuring of tissues for growth. 
Many factors have been reported to affect the rates of these protein degradative 
mechanisms. The general state of nutrient availability to the cell has an effect on protein 
degradation as well as protein synthesis. In incubated rat diaphragm, increases in the amount 
of glucose or leucine have been shown to decrease protein degradation.^ Leucine also 
stimulates protein synthesis, while glucose has no effect on protein synthesis.^ General 
starvation increased protein degradation in incubated rat skeletal muscle, while decreasing 
protein synthesis.^ However, a protein deficiency alone resulted in a decrease in both 
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protein degradation and synthesis. 
Many hormones have also been shown to affect protein degradation as well. Most 
of our knowledge in this area has come from work with skeletal muscle strips incubated in 
vitro or with cell cultures. Insulin has been shown to decrease muscle protein degradation, 
while increasing protein synthesis. Corticosteroids decrease degradation at 
physiological levels, while increasing degradation at pharmacological levels. Corticosteroids 
decrease protein synthesis at both levels. Thyroid hormone increases protein degradation 
and synthesis at both physiological and pharmacological levels. Growth hormone has been 
shown to increase protein synthesis and has been reported to have no effect on protein 
degradation.^^ Catecholamines have been shown to decrease protein degradation with no 
effect on protein synthesis. 
Other factors have been shown to alter protein degradation as well. Passive stretch 
and repeated stimulation of skeletal muscle strips have been shown to decrease protein 
degradation, while not effecting protein synthesis. Calcium ionophore has been shown 
to increase both protein degradation and synthesis, probably through effects on calcium 
dependent processes. The effects of Ca^^ ionophore could, in part, explain the higher rates 
of protein synthesis and degradation found in dystrophic muscles, which have a lowered 
ability to sequester Ca^"^ in the sarcoplasmic reticulum. Therefore, the variety of 
physiological conditions in the whole animal, such as hormonal balance, feeding or fasting, 
and amount of exercise, can lead to difficulties when trying to obtain controlled conditions 
for studying protein degradation. 
Study of the mechanisms of basic protein turnover in vivo is difficult at best. The 
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many different tissues interacting in the whole animal make controlled conditions almost 
impossible to attain. It is primarily for this reason that a variety of in vitro cell culture 
techniques have been adapted. In vitro systems using muscle strips, isolated muscles, 
or muscle cell cultures^^ have been valuable models for studying basic protein metabolism 
and the effects of compounds on muscle protein degradation. Muscle strips have an inherent 
disadvantage in that when the muscle is removed, the model system is in a state of net 
nitrogen loss. Muscle cell cultures, on the other hand, can be maintained in a state of 
nitrogen balance, which is desirable for studying protein degradation. Muscle cell cultures 
offer another advantage over muscle strips in that monolayer cell cultures have fewer 
diffusion problems and nutrients and added compounds are readily accessible to diffuse into 
the cells. For the study of muscle, three culture techniques available are used: primary, 
clonal myogenic, and transformed myogenic cells.^^ Each of these methods has advantages 
and disadvantages. The major advantage with the use of clonal myogenic cultures is that 
each cell is of the same type and genetic origin. However, the low density of clonal cultures 
makes biochemical measurements difficult. Transformed myogenic cell lines offer ease of 
handling and making biochemical measurements, but through transformation the growth 
characteristics of the cells change. Thus transformed myogenic cell lines may not respond 
to the same stimuli that the cells in the animal respond to. 
Primary cultures offer the best representation of cells in the animal, because they are 
derived directly from the embryonic or adult animal. As good a representation as these 
might be, problems associated with them include the fact that most primary muscle cell 
cultures are from embryonic sources and express embryonic isoforms of muscle proteins. 
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Secondly, myotubes found in culture are not true muscle fibers and the general conditions 
found in cell culture, i.e. lack of hormones and innervation, may affect phenotypic 
expression. Most importantly, however, these cultures often lack the uniformity of cell type 
found in the other culture systems. Contamination from other cell types, especially 
fibroblast in cultures derived from embryonic muscle tissue, can be a problem. Preplating 
during initial culture set up uses differential adhesion of the cell types to sort out non-
myogenic cell types, because the fibroblasts will settle out and stick to the plate and the 
myoblasts do not. Common methods to reduce this contamination after plating include 
killing dividing fibroblasts with the use of fluorodeoxyuridine®'^^ or cytosine 
arabinoside^^'^^ after myogenic cell fusion. Thus, with a combination of techniques, 
reasonably pure muscle cell cultures can be obtained. A new and promising method for 
obtaining pure primary cell cultures is to label the myogenic cells derived from the tissue 
with fluorescent antibodies and through sophisticated cell-sorting, separate these from the 
other cell types.^ Lastly, compounds in the culture medium may be readily transported 
into the cells and cellular metabolites readily transported out of all the cells. 
Typically in the study of protein degradation, radiolabelled amino acids have been 
used as tracer compounds. Long tehn labelling with radioisotopes is not generally used 
because of the possibility of the isotope being incorporated into many cellular components. 
This makes separation and counting of the particular compound of interest increasingly 
difficult as the labelling time with radioisotopes increases. Labelling to a high and constant 
specific activity is then difficult because of the amount of label needed and time necessary 
to achieve this. Two methods of determining protein degradation have been to measure 
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appearance of the tracer into the medium surrounding the cells^^ or to isolate the labelled 
protein from the cells and determine tracer activity in the protein. 
Stable isotope use to study biological mechanisms was shown to be feasible in the 
1930's with the use of deuterated compounds synthesized from deuterated water.^^ 
However, due to the widespread availability of radiolabelled compounds since the 1940's, 
and due to the processes previously involved with stable isotope analysis, these isotopes have 
commonly been chosen for use over stable isotopes. The past two decades have seen a 
renewed interest in stable isotope use in research. Aside from the safety advantages offered 
with their use,^ the isotope of nitrogen, allows this atom to be followed in protein 
metabolism, whereas, no radioisotope of N is of practical use.^^ Other advantages include: 
extremely long half-lives, multiple labelling of compounds, smaller isotope effects, and new 
gas chromatography/mass spectrometry equipment that allows analysis and quantitation of 
specific labelled compounds.^^ Labelling to a high or even 100 % specific activity of the 
tracer is possible with stable isotopes because the analysis is compound specific. For 
example, for labelling of proteins, every protein can be labelled to 100 % specific label 
activity therefore eliminating any chance that the results may be prejudiced through the 
mecanism by which proteins are chosen to be broken down. The disadvantages of costs, 
labor, and availability of labelled compounds associated with the use of stable isotopes are 
quickly disappearing. Probably the most important use to date for stable isotopes in 
biological research has been with the study of amino acid metabolism.^^'^®*^^ The use 
of ^H, and labelling of amino acids to determine kinetic studies offers a more 
precise method for determining macronutrient nutrition than previously characterized nitrogen 
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balance studies.^^ 
Although many methods may be used to determine relative protein degradation, an 
absolute rate of protein degradation is difficult to determine. Problems arise with the 
metabolism and reutilization of the tracer. Reutilization of tracer for protein synthesis during 
the course of the experiment gives rise to an over estimate of tlie half life if specific proteins 
are analyzed for tracer and an underestimate of protein degradation if release of tracer from 
the whole cell is measured.^® One method of avoiding reutilization is to use a non-
recyclable tracer such as 3-methylhistidine. Modification of a histidine residue in actin^^ 
and fast twitch myosin^^ provides a way to measure the degradation rate of myofibrillar 
proteins.^^ Unfortunately, 3-methylhistidine indicates only myofibrillar protein degradation 
and myofibrillar proteins only make up about 52-56 % of the proteins in the muscle cell.^'* 
Therefore, using 3-methylhistidine to measure protein degradation does not provide 
information about cytosolic protein degradation in the cell, which is a vital component of 
protein turnover. 
Alternatively, blocking protein synthesis prevents reutilization of labelled amino 
acids. ^  Cycloheximide has been used to block protein synthesis in most tissue^^ and cell 
culture systems.^^'^® Cycloheximide prevents peptide chain elongation during protein 
synthesis and will also cause polysome disaggregation.^^ The use of cycloheximide to 
resolve absolute rates of protein degradation assumes cycloheximide itself does not alter 
protein degradation, at least during the time course of the experiment. This assumption may, 
however, be erroneous, in that some investigators have reported that cycloheximide can 
eAect protein degradation in liver and muscle cells which have been induced by serum or 
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nutrition deprivation into higher than normal rates of protein degradation.^®'^^''^ If 
reutilization were blocked an increased rate of protein degradation should be measured with 
the addition of cycloheximide. However, in cultured fetal mouse hearts overall protein 
degradation was decreased by 18 % and cathepsin D activity decreased by 49 % after 24 h 
in response to cycloheximide/^ The effect of cycloheximide on protein degradation has 
been reported to start as early as 15-20 minutes after administration in liver cells.^^ Even 
so, cycloheximide continues to be used in the measurement of protein degradative 
rates. 
Two recent reviews, one by Goll et. al.^ and the other by Pearson and Young,^ show 
that although many proteinases and their cellular locations have been described, little is really 
known about how these degradative systems function to accomplish the general rate of 
protein turnover seen in muscle. Two major classes of proteinases are exopeptidases, which 
cleave proteins at their terminal ends and endopeptidases, which cleave proteins centrally. 
Proteinases can also be classified according to the amino acid residue involved in catalysis. 
Although most exopeptidases are metalloproteinases, endoproteinases fall into four major 
categories: serine proteinases, cysteine proteinases, aspartic proteinases, and metallo­
proteinases.^ Finally proteinases can be classified according to their intracellular location. 
General protein degradation inside the cell can occur in either lysosomes or in the cytoplasm, 
however, muscle cells generally contain fewer lysosomes than do other cell types.'^^ 
Lysosomal cathespins B, D, H, and L have been identified in muscle with cathepsin L 
having the greatest activity followed by H, B, and then Cathespins B, H, and L are 
cysteine proteinases, while D is an aspartic proteinase."^ Cathepsin activity in muscle is 
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such that all the protein in the cell could be degraded in 6-9 days/^ Numerous reports 
have agreed that lysosomal proteinases are responsible for about 25-35 % of the total protein 
turnover in muscle.'*®''^^'^® 
Muscle cells also contain neutral and alkaline cytosolic proteinases. Among these are 
/t-calpain,^^ m-calpain/^ multicatalytic proteinase,proteinase high-molecular 
weight cysteine proteinase,^'* hydrolase and ATP-ubiquiten-dependent 
proteinase.^® The calpains, /t-calpain (micromolar Ca^'^'-dependent proteinase) and m-
calpain (millimolar Ca^'^'-dependent proteinase), have been implicated in initiating 
myofibrillar protein degradation.^^ When isolated myofibrils are treated with m-calpain, 
Z-disk disintegration occurs,^^*^®'^^ followed by an increase in the number of easily 
released myofilaments.^^'®® Rats that were alternately starved, fed, then restarved had 
lower levels of calpains during the starvation and much lower levels during the restarvation 
periods than during the feeding period.®^ Also seen was a corresponding decrease in 
contractile protein to total muscle weight during the feeding period. Others have found, 
using 3-methylhistidine to measure muscle protein degradation, that during starvation 
myofibrillar protein degradation decreases.®^'®^ This association of the decrease in 
calpains during times of decreased myofibrillar protein degradation adds further evidence that 
calpains may participate in this process. This, however, does not indicate that the calpains 
alone initiate myofibrillar protein turnover. A naturally occurring inhibitor of the calpains, 
calpastatin, is also found in muscle®'* and has been shown to inhibit only the calpain 
proteinases. Calpastatin, like the calpains themselves, is activated by calcium.®^ Exactly 
how these proteinases act to degrade cellular proteins is unclear. However, the presence of 
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these proteinases in the cell probably indicates that they have a role in protein degradation. 
Many proteinases have been characterized as to what proteins they degrade in vitro, but, no 
clear evidence exists as to whether this activity carries over into the cell. 
Every proteinase undoubtedly has some synthetic or natural inhibitor. Much attention 
has been given to the inhibition of thiol and serine proteases, because most of the common 
proteases in muscle have either serine or thiol active sites. Leupq)tin and E-64, proteinase 
inhibitors of microbial origin, have been shown to be potent inhibitors of thiol 
proteinases.^^ In addition, leupeptin is a potent inhibitor of serine proteinases.^^ In the 
case of the calpains, inhibition can occur only after activation with Ca^'*'.^^ This would 
indicate that the thiol active site of the calpains is protected until activation with Ca^'*'. 
Likewise, inhibition of the multicatalytic proteinase inhibitor with chymostatin is also 
blocked before activation of this proteinase with sodium dodecylsulphate (SDS).^^ 
Bestatin, another lysosomal proteinase inhibitor, was used to treat perfused rat hindquarters 
of normal and diabetic rats.^^ The authors of this study showed that both leupeptin and 
bestatin decreased degradation in normal muscles, but that leupeptin did not have an effect 
on the higher rates of protein synthesis and degradation found with the diabetic condition. 
They did however find labelled acid soluble peptides in muscles treated with bestatin and not 
with leupeptin treatment, probably indicating that bestatin was inhibiting a different set of 
proteinases than was leupeptin. Key to further understanding of which proteinases degrade 
which proteins in vivo may be the ability to detect partially degraded proteins. 
The protease inhibitor leupeptin has probably been most studied. It has been shown 
to decrease protein breakdown in skeletal muscle cell cultures from both normal and 
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dystrophic chick lines. However, in normally growing rats no effect was seen on 
protein turnover or growthJ^'^^'^^'^^'^^ Leupeptin has been shown to decrease 
proteolysis during conditions of abnormal growth. For example, leupeptin has been shown 
to prevent or delay the effects of muscular dystrophy,denervation atrophy,^® long 
bone fracture,and elevated levels of glucocorticoids®® in vivo. 
Leupeptin is a naturally occurring tripeptide aldehyde with the structure of either N-
propionyl or N-acetyl-leucyl-leucyl-arginal.®^'®^ Leupeptins were originally isolated 
from various species of actinomycetes.®^ The aldehyde functional group on the C-terminus 
is key to the inhibitor's activity^^, because it acts by forming a covalent hemiacetal or 
thioacetal adduct in the active site of serine and cysteine proteinases, respectively.®^'^ 
Leupeptin is a broad-based inhibitor that inhibits a variety of proteinases: plasmin, trypsin, 
kallikrein, thrombokinase, papain,®^ cathepsin and the calpains.®®'®^ Much 
research conducted with leupeptin shows inhibition of protein degradation in muscle cells to 
be variable with effects ranging from 10-54 %. Riebow and Young^® reported that most 
of the effect of leupeptin is on the soluble cell proteins and that leupeptin has little effect on 
myofibrillar protein degradation. Libby and Goldberg®® reported that in cultured 
embryonic chick muscle cells leupeptin decreased general protein degradation by 7-13 %. 
Many analogs of leupeptin exist from biological sources®^ and two new analogs of 
leupeptin have been chemically synthesized. These new analogs are thought to be specific 
and potent inhibitors of the calcium activated neutral proteinases (calpains).^ These 
inhibitors, named calpain inhibitors I and II, have the structures N-acetyl-leucyl-leucyl-
norleucinal and N-acetyl-Ieucyl-leucyl-methioninal, respectively.®® They are 2-5 times more 
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active than leupeptin in enzyme assays using pepsin, /t-calpain, and m-calpain,'° but their 
effect has not been tested in cultured cells or animals. If, as previously described, the 
calpains are pivotal in initiating myofibrillar protein turnover,then these calpain 
inhibitors could be potent inhibitors of protein degradation in muscle cells. 
Animal growth research has for many years concentrated on the results and ignored 
the mechanisms. This has in part been because methods to elucidate the mechanisms have 
been beyond our capabilities. Much energy is expended as proteins are continuously turned 
over during growth. An understanding of protein degradation and possible methods for 
lowering of this rate would be advantageous, as this would lead directly to increased protein 
accretion. This would also save the energy costs involved in part of the protein turnover. 
Surprisingly, good methodology for measuring protein turnover has been hard to resolve. 
In vitro model systems are useful tools for performing basic protein turnover studies. Thus, 
the following series of three papers contained in this dissertation will describe experiments 
conducted to first derive a method using stable isotope labelling to compare the relative rates 
of proteolysis in primary embryonic chick skeletal muscle cell cultures and the effects added 
compounds have upon it. Stable isotope labelling methods offer advantages over 
radioisotopic labelling methods as previously mentioned, however, they have not been widely 
applied to culture systems. We applied this methodology to examine the effects of the 
proteinase inhibitors, leupeptin, calpain inhibitor I, and calpain inhibitor II, on protein 
degradation in cell culture. Although cycloheximide is commonly used to determine rates 
of absolute protein degradation, its effect on degradation has been largely ignored. In the 
development of the stable isotope labelling methodology, cycloheximide was used to in an 
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attempt to determine an absolute rate of protein degradation. The absolute rate of protein 
degradation should be greater than the rate of protein degradation measured without 
cycloheximide. A second set of experiments will be conducted, using the methodology 
described in section I to examine the effect cycloheximide might have on protein 
degradation. Lastly a series of experiments to examine the in vivo effects of the proteinase 
inhibitors, leupeptin and the calpain inhibitors I and 11, on the growth of young chicks will 
be conducted. The in vitro data from the first experiments will be compared with the in vivo 
data obtained in the last experiments. 
EXPLANATION OF DISSERTATION FORMAT 
This dissertation was prepared using the alternate format, as described in the Iowa 
State University Graduate College Thesis Manual (1990). This format allows for the 
preparation of independent papers that are suitable for submission to scientific journals. 
Each section of this dissertation is a complete paper containing an abstract, intiroduction, 
materials and methods, discussion, and references. The format followed for headings, 
tables, and general form is that required by The Journal of Nutritional Biochemistry. The 
similarity of the topics contained in the three sections allowed for preparation of general 
introduction and summary and discussion sections. 
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SECTION I. USE OF A STABLE ISOTOPE METHODOLOGY FOR 
STUDYING THE EFFECTS OF LEUPEPTIN, CALPAIN 
INHIBITOR I, AND CALPAIN INHIBITOR H ON 
PROTEIN TURNOVER IN EMBRYONIC CHICK 
SKELETAL MUSCLE CELL CULTURES 
16 
Use of a stable isotope methodology for studying the effects of leupeptin, calpain inhibitor 
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cultures. 
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ABSTRACT 
The objective of this study was to develop a stable isotope methodology to determine 
the effects of leupeptin and two leupeptin analogs (calpain inhibitors I and II) on protein 
turnover in embryonic chick skeletal muscle cell cultures. Primary embryonic chick skeletal 
myotube cultures from 12-day White Leghorn type chick embryos were used for in vitro 
testing of inhibitor activity. Myoblasts from leg and thigh muscles were removed and plated 
on 60-mm collagen-coated plates (5.5 X 10® cells/plate). Cultures were grown for 7 days 
in 3 ml per plate of Dulbecco's MEM, supplemented to contain all 20 amino acids, 10% 
horse serum, 2.5% embryo extract, 50 lU penicillin G/lOO ml, and 1 % Fungizone. Cultures 
were grown in a 5% CO2 atmosphere at 37'C and 90% humidity, and the culture medium 
was changed every 24 h. On days 5 and 6, medium containing 5 X 10'^ M cytosine-jS-D-
arabinofuranoside was fed to kill any dividing cells and leave a relatively pure culture of 
fused, nondividing myotubes. On day 8, cultures were rinsed with phosphate buffered 
saline, and fresh medium was added containing the protease inhibitors. Depending on which 
labelling protocol was used, the medium added on day 8 contained either 25 or 100% of the 
normal leucine as natural leucine or 100 % of the normal leucine as [5,5,5]-^H3-leucine. 
During the next 24 h, measurement of the isotope of leucine of interest into the release 
medium was used as an indication of relative proteolysis. Three plates per treatment were 
used for each experiment. Two replicate experiments were conducted for each set of data. 
Sampling times of 1, 8, and 24 h were determined adequate for describing the release of the 
label used. Further experiments showed that either l-^'^C-leucine labelling for 24 h or 
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[5,5,5]-^H3-leucine labelling during the entire growth period would show a significant 
(P<0.05) decrease of 6-20 % in isotope appearance into the medium with leupeptin 
treatment. Final labelling methods showed no difference in correcting for utilization of 
leucine Arom the medium whether decrease of ^H-leucine or the isotopic leucine in the 
medium was used to calculate the correction. The last set of experiments, in which cells 
were grown in natural leucine and the release medium contained ^Hg-leucine, described the 
effects of the calpain inhibitors I and n on protein degradation. Calpain inhibitor I 
significantly (P<O.OS) decreased release of natural leucine from cells after correction for 
^Hg-leucine utilization by 45, 55, 63, and 60 % over the period from 1 to 24 h for 
treatments of 7, 23, 70, and 93 /ig/ml, respectively. Calpain inhibitor 11 showed a dose 
response with each successive level significantly (P<0.05) further decreasing release of the 
natural leucine up to the 70 /Lig/ml level. Decreases from 1 to 24 h were 11,48, 61, and 64 
% for respective treatment levels of 7, 23, 70, and 93 ng/nA. 
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INTRODUCTION 
Important to the study of meat animal growth is the production of lean tissue, i.e. 
skeletal muscle. Knowledge of skeletal muscle protein metabolism is important if we are to 
make the process more efficient. Skeletal muscle growth may be defined as the relatively 
small difference between protein synthesis and degradation in skeletal muscle tissue. 
Because protein synthesis is a much more costly operation in terms of energetics than protein 
degradation, decreasing the rate of protein degradation would have a greater effect in 
increasing the growth rate than would increasing the rate of protein synthesis^ Thus, it is 
of prime importance to be able to determine the effects of added compounds on muscle 
protein degradation. A commonly used technique for in vivo turnover studies is to 
constantly infuse labelled amino acid until a plateau in plasma values is reached and protein 
turnover can then be studied.^ Unfortunately, extracting information about muscle protein 
degradation from whole animal studies is a difficult procedure that can lead to error in 
measurement of muscle protein turnover. Thus, in vitro systems using muscle strips,^ 
isolated muscles,'^ or muscle cell cultures^ have been valuable models for examining effects 
of compounds on muscle protein degradation. 
Young and coworkers^'® described the use of chick skeletal myotube cultures derived 
from embryonic myogenic cells, that have been allowed to differentiate and fuse, as a model 
system for studying muscle protein degradation. Such cultures have been shown to be in a 
steady state of nitrogen metabolism. Because these cultures are an example of a living 
tissue, in contrast to isolated muscles, they provide a valuable model for the study of protein 
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metabolism. Traditional methods for measurement of protein degradation in cell cultures 
have involved using a labelled precursor, radiolabelled amino acid, to label cell protein. Cell 
proteins are then isolated at selected times and analyzed to determine the disappearance of 
label from the proteins.^ For use in cell cultures this methodology has a major inherent 
drawback in that separate culture plates must be used to obtain results for each time point. 
Because this method involves measuring and comparing results of one plate with those from 
another plate to obtain a time curve representing protein degradation, a large number of 
cultures must be used to reduce errors due to variation among plates. While this duplicate 
plate technique can provide additional information relating to specific cellular proteins, we 
were interested in developing a simpler and more sensitive test for examining the effects of 
added compounds on overall cellular protein degradation. By utilizing the same culture plate 
to make multiple measurements, errors, such as those associated with measuring cell protein 
and converting all the data, are eliminated and fewer replicate plates should be necessary to 
detect differences. Thus, we used a method involving measurement of release of label into 
the cell culture medium. The procedure involved using either radiolabelled leucine or stable 
isotopes of leucine to prelabel myotube cultures. Use of stable isotopes, analyzed by gas 
chromatography-mass spectrometry, offers the additional advantage of one step identification 
and quantification of the labelled compound.^ 
Leucine has been shown to be a useable tracer amino acid to study protein 
metabolism in cell cultures^'^ and whole animals.^ In rat L6 myoblasts the use of leucine, 
histidine, or tyrosine to prelabel the cell proteins to study the effects of serum, NH4CI, 
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insulin, and cycloheximide showed essentially the same results no matter which amino acid 
was used.^^ The results obtained with leucine labelling were equal to those obtained with 
tyrosine labelling and the differences in the results seen with the histidine label were reported 
to be due to the lower label incorporation when compared to either leucine or tyrosine. 
Because leucine could be analyzed directly, and long labelling times could be used with the 
stable isotopes, we used leucine isotopes to prelabel intracellular proteins. It has been 
reported that at leucine levels of 0.5 mM and greater, the specific activity of a label in the 
medium pool is similar to the specific activity found in the intracellular pools. In Chinese 
hamster ovary cells, leucine levels comparable to the levels found in primary muscle cell 
culture, 0.8 mM, result in 95% of t-RNA charging from medium pools of leucine. This 
would allow comparisons using measurements made of label pools in the medium to be used 
to make relative comparisons between various treatments applied to the cultures that might 
effect leucine metabolism. 
The protease inhibitor leupeptin has been shown to decrease protein breakdown in 
skeletal muscle cell cultures from both normal and dystrophic chick lines.^'^^ Riebow and 
Young^ suggested that soluble rather than myofibrillar protein turnover was inhibited. 
Leupeptin is a tripeptide aldehyde with the structure N-acetyl-leucyl-leucyl-arginal^'*' 
and the aldehyde functional group on the C-terminus is key to the inhibitor's activity, 
because leupeptin forms a covalent hemiacetal or thioacetal adduct in the active site of serine 
and cysteine proteinases, respectively. Leupeptin inhibits a variety of proteinases: 
plasmin, trypsin, kallikrein, thrombokinase, papain, cathepsin and the 
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calpains.^^'^® Because leupeptin is known to inhibit proteolysis, treatment of cell 
cultures with this compound provides a valid test to examine the labelling method. Structural 
modification of leupeptin may alter enzyme specificity. Two analogs of leupeptin have been 
chemically synthesized, and these are thought to be potent inhibitors of the calpains^^ 
These inhibitors, named calpain inhibitors I and n, have the structures N-acetyl-leucyl-
leucyl-norleucinal and N-acetyl-leucyl-leucyl-methioninal, respectively.^^ They are 2-5 times 
more active than leupeptin in enzyme assays,^^ but their effect has not been tested in cultured 
cells. Thus, the overall objective of this study was to develop stable isotope methodology 
suitable for determining the effects of added compounds on protein degradation and to use 
this method to examine the effects of leupeptin and its synthetic analogs, calpain inhibitors 
I and n, on protein turnover in embryonic chick skeletal muscle cell cultures. 
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MATERIALS AND METHODS 
Muscle cell cultures: 
Two sources of eggs were used in these studies. First, for the preliminary studies, 
fertile eggs from a layer strain of chicken were obtained from Hy-Line (Dallas Center, lA) 
and incubated for 12 days in a Leahy egg incubator. Later experiments were done with 12-d 
incubated specific pathogen free (SPF) eggs from a layer strain of chicken, obtained from 
Hy-Vac Laboratory Eggs (Gowrie, lA). The preincubated SPF eggs offer ease of use and 
a higher sterility level. SPF preincubated eggs are currently used for all primary chick 
skeletal muscle cell cultures, and were used for the last calpain inhibitor I and H experiments 
reported in this paper. 
Methods for isolation and culture of myogenic cells were similar to those of Ridpath 
et. alP" Embryos were removed, muscle tissue from the legs was isolated after removal 
of as much skin and bone as possible, and the tissue was placed in 10 ml of the cell culture 
medium described below. The suspension was dissociated by mixing with a vortex mixer 
for about 2 min and then filtered through cheesecloth. The larger pieces were resuspended 
in 10 ml of medium, vortexed and filtered again, and the second filtrate combined with the 
first filtrate. The resulting 20 ml suspension of cells was filtered two times through separate 
sterile Swiney filters fitted with a 400x400 nylon mesh (National Filter Corp. Hamden, CT), 
to remove any remaining clumps of cells. Cells were collected by centrifuging the filtrate 
at 700 g for S minutes, and the cell pellet resuspended in 20 ml of medium. This suspension 
was pre-plated on a 100 mm uncoated Falcon (Becton Dickinson Labware, Oxnard, CA) 
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culture dish and incubated at 37*C for 40 minutes as described below for muscle cultures. 
After pr^lating, the medium containing non-adherent cells was carefully poured off, mixed 
by pipetting, and the cells counted in a hemocytometer. The suspension was diluted with 
medium to a density of 2x10^ cells per ml. Falcon 60x15 mm cell culture plates had been 
coated with Vitrogen 100 (Collagen Corp., Palo Alto, CA) diluted 1:10 with buffered saline 
solution (BSS) (137 mM NaCl, 2.7 mM KCl, 1 mM CaClj, 1 mM MgClj, 0.15 mM 
NaH2P04, 1.36 mM Na2HP04, 6 mM NaHCOg, 5.5 mM glucose, pH 7.4) and allowed to 
dry in sterile air during preparation of the cells. Three ml of the suspension was then 
pipetted onto each of the collagen coated culture plates. 
Cultures were then incubated in a Nuaire (Plymouth, MN) cell culture incubator set 
for 37* C, 5 % CO2, and 90 % relative humidity and medium was replaced every 24 hours 
with 3 ml of warm fresh medium. Medium for general muscle cell culture contained 500 
ml Dulbecco's modified eagle medium (DMEM deficient, low glucose, powdered form, 
Sigma Chemical Co., St. Louis, MO), 60 ml horse serum (Gibco BRL, Grand Island, New 
York), 15 ml chicken embryo extract (see below), 6 ml of penicillin G solution (Gibco, 
resulting in 50 lU/ml of media), and 3.25 ml Fungizone (Sigma, St. Louis, MO, resulting 
in 1.39 fig amphotericin B/ml in the media). The Dulbecco's medium was supplemented to 
contain all 20 amino acids to limit any use of amino nitrogen for transamination. Final 
levels of amino acids are shown in Table 1. 
Labelling and feeding schedule is shown in Table 2. The basic procedure for 
preparation and labelling of the myotubes is similar to that of Riebow and Young,^ except 
25 
Table 1 Amino acids in supplemented DMEM. 
Amino acid mg/1 
L-alanine^ 50. 
L-arginine-Hcl 84. 
L-asparagine^ 88. 
L-aspartate^ 60. 
L-cystine*2HCl 62.6 
L-glutamate^ 150. 
L-glutamine 584. 
Glycine 30. 
L-histidine-HCl-HjO 42. 
L-isoleucine 105. 
L-leucine 105. 
L-lysineHCl 146. 
L-methionine 30. 
L-phenylalanine 66. 
L-proline^ 80. 
L-serine 42. 
L-threonine 95. 
L-tryptophan 16. 
L-tyrosine*2Na*2H20 103.8 
L-valine 94. 
^Amino acids added to standard DMEM. 
that cytosine fi-D-aribinofiiranoside (CA) (Sigma) was used to kill dividing fibroblasts aAer 
myoblast fusion.^ A stock solution of 0. IM CA was prepared and kept refrigerated. This 
was added at the rate of 50 /tl/100 ml of complete medium to give a fmal concentration of 
5x10"^ M CA. Three levels of CA were originally tried, 1x10"^, 5x10*^, and 1x10"^ M. 
The 5x10'^ M level gave the highest level of fused cells and the healthiest looking cultures 
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Table 2 Culture schedule. 
Day Procedure 
0 Set up cell cultures 
1-4 Feed cells 3 ml medium daily 
5-6 Feed cells 3 ml medium containing S x 
10'^ M cytosine 8-D-aribinofuranoside 
daily 
7 Feed cells 3 ml medium 
8 Feed cells 3 ml medium plus any 24 hour 
isotopic leucine label 
9 Rinse plates and add 3.2 ml release 
medium containing a different isotope of 
leucine than had previously been used 
during labelling 
as determined by microscopic examination. 
Protein determinations were made on 8 and 9 d old cell cultures. Culture plates were 
rinsed 3 times with phosphate buffered saline, 4 ml of 3 N NaOH was added to each plate, 
and the plates were allowed to sit for at least 1/2 h at room temperature. Protein 
determinations were made in triplicate according to the instructions with the Bicinchoninic 
Acid Protein Assay Kit (Pierce, Rockford, A standard curve of bovine serum 
albumin was used for comparison of sample readings. 
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Chicken embryo extract: 
Twelve-day Hy-Line chick embryos were aseptically removed from the eggs, placed 
in a large culture plate, and rinsed twice with BSS. Embryos were then decapitated and 
homogenized by expelling them twice through a 50 ml disposable syringe. An equal volume 
of BSS was added to the embryo homogenate, and the mixture was allowed to stand at room 
temperature for one half hour. The mixture was then centrifuged at 2,000 g for 20 min, and 
the supernatant was stored frozen for up to six months. When thawed, the embryo extract 
was again centrifuged and the supernatant used for medium preparation. 
Stable isotope labeling: 
For the first labelling method, [5,5,5]-^Hg-leucine (Tracer Technologies Inc., 
Newton, MA) was added to leucine deficient DMEM, prepared as before, and made up one 
half of the normal 105 fig leucine/ml used in the medium. This medium was fed on days 
2 through 8 to label all cellular proteins. Medium used during the measurement of the 
release of the labelled leucine was the same as regular DMEM, except only 25 per cent of 
the normal amount of leucine, as natural leucine, was added. This procedure was used for 
the initial studies with leupeptin. ^H^-leucine was incorporated into cellular proteins during 
the labelling period and released into the medium through protein degradation during the 
measurement period. The ^H^-leucine was then be detected in the release medium containing 
natural leucine as the only source of leucine. 
The second labelling method measured release of natural (unlabelled) leucine into 
release medium containing ^H^-leucine. Release medium was again made starting with 
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leucine-free base to which was added all ^H^-leucine at a concentration of 105 ^g/ml. 
Appearance of natural leucine in the isotopic release medium was then measured. 
Radioisotope labeling: 
For 1-^^C-leucine labelling, 2500 nCi of l-^'^C-leucine (Amersham, Arlington 
Heights, IL, 342 mCi/mmole) was dried under nitrogen gas, diluted to 2 ml volume with 
water, and sterilized by filtration. Labelling of the cell cultures with ^'^C-leucine was started 
24 hours before the measurement period by the addition of 6 /il (approx. 5 nCi) of the 1-
^'^C-leucine solution to each plate. 
To determine loss of leucine from the medium used to measure release of label from 
prelabelled protein (release medium), 5000 /iCi of ^H-leucine (Amersham, Arlington 
Heights, IL, approx. 50 mCi/mmole) was dried under nitrogen gas, diluted to a volume of 
2.5 ml with water, and sterilized by filtration. ^H-leucine was added to the medium at the 
start of the measurement period by adding 8 /û (approx. 5.0 fid) of ^H-leucine solution to 
the 10 ml of release medium used for each treatment. In the second set of experiments, in 
which radioisotopes were used, the ^H-leucine had been diluted and addition of 20 n\ 
(approx. 2.7 /tCi) gave increased accuracy in dpm at the start of the experiment. 
Figure 1 shows the typical labelling protocol used in the experiments, where stable 
isotope labelling was used for several days and radioisotope labelling was used for the 24 h 
before measurement. 
Collection and processing of samples: 
At the end of the labeling period the medium was removed and the cells were washed 
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Release medium added 
Samples taken 1, 8, 24 h 
Radioisotope labelling  ^
Stable isotope labelling 
1 2 3 4 5 6 7 8 9  
Day 
Figure 1 Labelling methods for stable- and radio- isotopes in the cell culture medium during 
the cell culture growth. 
once with warm phosphate buffered saline solution (3.3 mM NaH2P04, 6.7 mM Na2HP04, 
and 150 mM NaCl, pH 7.0) and the release medium added. 20 ^1 samples of media were 
taken for gas chromatography/mass spectrometer measurement and scintillation counting 
(Beckman LS1700 liquid scintillation counter) at selected times during the release period 
depending on the week's experiment, as described in the results. For scintillation counting 
the 20 fil samples were deposited into scintillation vials directly from the plates and 2 ml of 
cocktail (Scintiverse BD, Fisher, Pittsburg, PA) was immediately added. For the GC/MS 
analysis, media samples were immediately frozen and then dried at 70*C under nitrogen gas 
as soon as possible. Dried samples were derivatized with 100 nl acetylnitrile plus 100 jul 
N-methyl-N-(t-butyl-chlorosilane)-trifluoroacetamide containing 1 % /-butyldimethylchloro-
30 
silane (Regis Chemical Company, Morton Grove, JL)? Derivatized samples were then 
heated for 1 h at 70* C to complete the derivatization process. Natural and ^H^-leucine were 
measured at 302 and 305 AMU, respectively, by using a gas chromatography-mass 
spectrometry system (Hewlett-Packard 5970A). Quantitation of leucine was calculated using 
an internal standard, norleucine, which was added prior to drying the samples. Values were 
then corrected for evaporation from cell plates during the measurement period and also for 
loss of volume due to sampling. 
Inhibitors: 
Leupeptin was obtained from Sigma Chemical Co. (St. Louis, MO). In the initial 
studies, leupeptin was dissolved in water, and the solution was filtered through a 0.2 jum 
syringe filter and added to the release medium at time 0. Leupeptin is readily soluble in 
water. A stock leupeptin solution was used, of which 0.75 ml was added per 10 ml of 
release medium. Concentrations of 93, 70, and 46 /tg/ml were obtained by varying the 
concentration of leupeptin in the stock solution. Control plates received 0.75 ml of sterile 
water per 10 ml of release medium. Calpain inhibitors I and II were obtained from 
Boehringer Manheim (Indianapolis, IN). The calpain inhibitors were dissolved in 95% 
ethanol, and the resulting solution was diluted with water to yield a 25% ethanol stock 
solution containing 1.34 mg inhibitor/ml. Ethanol was used because the calpain inhibitors 
were insoluble in culture medium alone. Treatments were applied to cultures at 0.75 ml/10 
ml of release medium, and the added inhibitor concentration in the 0.75 ml was adjusted so 
that inhibitor concentrations of 93,70,23, and 7 /xg/ml were obtained. For the experiments 
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in which the effects of the calpain inhibitors were examined, leupeptin was also solubilized 
in ethanol, and the control plates received the same ethanol mixture without inhibitors. 
Leupeptin, known to inhibit protein degradation in our system, was included at 70 /tg/ml 
with each calpain experiment as a test that our methodology was working. 
Statistics and calculations: 
Differences between treatments were assessed by using analysis of variance with the 
General Linear Models procedure of SAS (SAS Institute Inc., Gary, NC). Individual 
treatment means were compared by using the least squares means calculations in the case of 
unequal replication and Duncan's multiple range test for means where replication was the 
same. Experiments were repeated in each of two weeks. Week to week variation was 
removed in the model by using experiment number as a covariate. Therefore a model of the 
parameters estimated would be: Yjj^=n + /STj + aWj + Error^jj, where Y;j|;=observation, 
/t=population mean, j8Tj=treatment effect, aWj=week to week variation, and Errorij,j=lack 
of fit for observation Yjjjj. By removing the variation due to week, instead of converting all 
the data to a common unit, the power of our test was increased. 
Loss of either ^H-leucine or ^Hg-leucine from the release medium was used to 
determine loss of leucine from the release media during the measurement period (due to 
protein synthesis or oxidation of the leucine). Values for release of label from cell protein 
were corrected as follows: 
corrected 8 h =0.5*(V2+Vg)*% decreasei.g+Vg; 
corrected 24 h=0.5*(Vi+Vg)*% decreasei.g+0.5*(Vg+V24)*% decreaseg.24 + V24; 
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where: 
Vj=value, either cpm or /ixg/ml, for labelling isotope released into the medium at 1 h, 
Vg=value, either cpm or /xg/ml, for labelling isotope released into the medium at 8 h, 
V24=value, either cpm or /xg/ml, for labelling isotope released into the medium at 24 h, 
% decreasei.g=loss of or [5,5,5]^H3-leucine from the release medium from 1 to 81) 
and % decreaseg.24=loss of or [5,5,5]^ H3-leucine from the release medium from 8d 
24 h. 
33 
RESULTS 
Cell culture protein determinations: 
Measurement of the amount of total protein per plate showed the result, mean±sem, 
of 15 samples on each of d 8 and 9 over a 4 week period to be 3.12±0.19 and 3.19±0.19 
mg of protein per culture, respectively. Analysis of the samples by week showed weekly 
averages for d 8 and 9 to be 3.16±0.18 and 3.23±0.19 mg of protein per culture, 
respectively. These data indicate that protein metabolism was in a relatively steady state 
when the measurements were made on the cultures and that about the same amount of protein 
per plate was obtained from week to week. 
Release of radioisotope from prelabelled cells: 
The first experiment was conducted to determine how many sampling points were 
necessary over the 24 h sampling period to describe the relative rates of isotope release from 
the prelabelled cell cultures. Release of 1-^'^C-leucine into the medium from cells prelabelled 
for 24 h is shown in Table 3. Sampling times ranged from 30 to 1440 min. Compared to 
the control values obtained, leupeptin at 70 ng/ml signifîcantly (P<O.OS) decreased release 
of 1-^^C-leucine from the cells at all times from 240 to 1440 min. Initial experiments 
showed that 1, 8, and 24 h sampling times produced a curve that equalled one obtained by 
using more sampling times. Regression equations, also shown in Table 3, show that whether 
just the 60, 480, and 1440 min time points were used in the regression or if all the points 
were used in the regression, the equations obtained were similar. Most of the experiments 
reported used sampling times of 60, 480, and 1440 min. 
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Table 3 l-^'*C-leucine (cpm) release from 24 hour prelabelled cells in the presence and 
absence of 70/xg leupeptin/ml. 
Treatment^ 
Time^ Control Leupeptin SEM^ 
30 861 870 17.0 
60 953 939 18.4 
90 1044 1012 19.6 
120 1127 1074 21.4 
240 1400 1308® 20.3 
360 1618 1513® 21.7 
480 1851 1680® 28.9 
1080 2499 2278® 41.8 
1440 2846 2535® 29.9 
Regression equations obtained using either all points or 1, 8, and 24 h 
points. 
All points 
Control Y=-7.029X10^X2+2.380X + 834 
Leupeptin Y=-6.052xl(Mx^4-2.037X + 833 
1, 8, and, 24 h points 
Control Y=-7.983xl0r4x2+2.569X + 802 
Leupeptin ¥=-6.331x10^x2+2.106X + 815 
^Results are from 6 plates, 3 in each of two weeks and are cpm per 20 /xl media 
sample. Means with superscripts vary significantly (P<0.05) from 
the other treatment mean. Where no superscripting occurs, no significant 
difference exists. 
^Minutes after changing to release medium containing unlabelled leucine. 
^Pooled standard error of the means for each time point. 
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Use of stable isotope labelling with 46, 70, and 93 fig/ml levels of leupeptin: 
The next experiment conducted compared the use of a stable isotope, ^H^-leucine, 
with that of the radioisotope, l-^'^C-leucine. The results of treatment with leupeptin at 
concentrations of 46, 70, and 93 /ig/ml in the culture medium are shown in Tables 4 and 5. 
Cells were prelabelled with medium containing ^H^-leucine, at one half of the leucine in the 
medium, on days 2 to 8 and l-^'^C-leucine for 24 h on day 8. ^H-leucine was added to the 
release medium, which contained natural leucine at 26 ^g/ml or 25 % of the normal leucine 
amount, at time 0 to indicate leucine utilization from the medium. In the initial experiments 
in which only part of the leucine used to label cell proteins was isotopic leucine, release 
medium contained 25 % of normal leucine to facilitate stable isotope analysis by decreasing 
the dilution factor. In Table 4 uptake of ^H-leucine, release of 1-^'^C-leucine from cellular 
proteins, and release of l-^'^C-leucine corrected for ^H-leucine uptake are shown. Variations 
in initial ^H-leucine seen were the result of adding very small quantities of labelled 
leucine to the medium. Treatment with leupeptin at all concentrations tested resulted in 
significantly (P<0.05) decreased release of l-^'^C-leucine. Percentage decrease due to 
leupeptin treatment from 2 to 24 h was 9-20 % before correction and 6-13 % after correction 
for ^H-leucine uptake. There were no significant differences among the treatment effects due 
to different leupeptin concentrations either before and after correction for ^H-leucine 
utilization. Table 5 shows the results of leupeptin treatment on release of the ^Hg-leucine 
both corrected and uncorrected for ^H-leucine uptake and on total leucine in the medium. 
^Hg-leucine release was decreased significantly (P<0.05) from 2 to 24 h by 17-24 % 
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Table 4 l-^'^C-leucine (cpm) release from cells prelabelled for 24 hours and ^H-leucine 
(cpm) disappearance from the release medium.^ 
Time (hr) 
Isotope 2 8 24 
Treatment Qig inhibitor/ml) 
^H-leucine (added to release medium at time 0)^ 
Control 4945 4581 3931 
Leupeptin (46) 5253 4742 3986 
Leupeptin (70) 6206 5657 4809 
Leupeptin (93) 7825 7152 6063 
SEM^ 326 293 271 
l-^'^C-leucine (prelabelled for 24 h) 
Control 1511 1957^ 2432® 
Leupeptin (46) 1451 1780®'' 2189*' 
Leupeptin (70) 1360 177iab 2200^ 
Leupeptin (93) 1330 V12& 2113'' 
SEM^ 65 62 70 
l-^'^C-leucine corrected for decrease in ^H-leucine'^ 
Control 2090 2891® 
Leupeptin (46) 1927 2648'' 
Leupeptin (70) 1914 2656'' 
Leupeptin (93) 1865 2566'' 
SEM^ 70 80 
^Data are presented as cpm per 20 /xl media sample. Results are from 6 plates, 3 in each 
of two weeks. Means within times without common letters in the superscripts vary 
significantly (P<0.05) from the other treatment means. Where no superscripting occurs, 
no significant difference exists. 
^Differences in initial ^H-leucine were from adding a small amount of solution to the 
medium. Percentage decreases were 21, 24, 23, and 23 for control, 46, 70, and 93 ng 
leupeptin/ml, respectively. 
^Pooled standard error of the means for each time point. 
^Corrected using ^H-leucine utilization from the release medium as described in Materials 
and Methods. 
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Table 5 Leupeptin effect on release of the stable isotope ^H^-leucine and total leucine 
(/tg/ml) in the release medium.^ 
Isotope Time (hr) 
Treatment^ 2 8 24 
^Hg-leucine (prelabelled on d 2 to 8) 
Control (0) 0.829» 1.39® 2.27® 
Leupeptin (46) 0.665®'' hOS^» 
Leupeptin (70) 0.593'' 1.04'' 1.79'' 
Leupeptin (93) 0.600'' l.OO'' 1.69'' 
SEM^ 0.064 0.069 0.102 
^Hg-leucine corrected for decrease in ^H-leucin^ 
Control (0) 1.46® 2.60® 
Leupeptin (46) 1.06'' 2.12'' 
Leupeptin (70) 1.15'' 2.07'' 
Leupeptin (93) I.IO'' 1.96'' 
SEM2 0.076 0.120 
Total leucine in release medium 
Control (0) 24.05® 23.66® 21.71® 
Leupeptin (46) 21.96®'' 20.21'' 19.72'' 
Leupeptin (70) 21.69®'' 19.64'' 19.63'' 
Leupeptin (93) 21.18'' 19.13'' 19.14'' 
SEM2 0.821 0.586 0.535 
^Results were from 6 plates, 3 in each of two weeks. Means within times without 
common letters in the superscripts vary significantly (P<0.05) from the other treatment 
means. Where no superscripting occurs, no significant difference exists. 
^Pooled standard error of the means for each time point. 
^Corrected using ^H-leucine utilization from the release medium as described 
in Materials and Methods. 
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before and 18-23 % after correction for ^H-leucine utilization. This difference was seen 
regardless of leupeptin level used and at both 8 and 24 h. Total leucine levels were also 
significantly (P<O.OS) less with leupeptin treatment because the amount released into the 
medium was less, and also because the decreased leucine available from degradation caused 
an increase in the amount of leucine utilized from the medium. As with l-^'^C-leucine 
release from the cells there were no differences among the leupeptin treatments, i.e. the 
same response to leupeptin was seen with the lowest dose as with the highest doses. 
Release of natural leucine from cells into ^Hg-leucine containing medium: 
Use of the stable isotope, ^H^-leucine, to label cell proteins, worked satisfactorily, 
however, use of this method required a large amount of isotope for labelling. There was 
more potential for isotope effect to have altered the rate of protein synthesis or degradation 
by feeding isotopic medium every day. Also, the radioisotope ^H-leucine, which was used 
to determine utilization, required a separate analysis. Therefore, an alternative procedure 
was developed. Cells were fed medium containing natural leucine during the culture period 
and on day 8 the release medium used contained ^H^-leucine at 105 ng/ml. By 'labelling' 
all leucines in cell proteins, the 105 ng/ml level of leucine could be used in the release 
medium. Again the 24 h pulse labeling with l-^'^C-leucine and addition of ^H-leucine in the 
release medium to correct for utilization were used. ^H-leucine was again included for 
comparison with ^Hg-leucine, which was also utilized from the release medium. The data 
for release of natural and l-^'*C-leucine from the cells, as well as the amounts of the ^Hg-
and ^H-leucine utilization from the medium are shown in Table 6. Sampling times of I, 8, 
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Table 6 Inhibitor effect on utilization of and ^H^-leucine from the release medium and 
release of the natural and l-^'^C-leucine from prelabelled cells into the release 
medium.^ 
Iso«,pe , 2, 
Treatment (fig inhibitor/ml) 
^H-leucine (added to release medium at time 0)^ 
Control 3117 2959 2647 
Leupeptin (70) 3245 2890 2557 
Calpain Inhibitor I (93) 3200 3067 2813 
Calpain Inhibitor n (93) 3403 3174 2890 
SEM^ 68 48 38 
^Hg-leucine (isotope in release medium)^ 
Control 108.7 93.3 77.5 
Leupeptin (70) 111.6 91.1 72.2 
Calpain Inhibitor I (93) 103.6 99.4 83.6 
Calpain Inhibitor II (93) 114.1 94.4 77.3 
SEM^ 3.49 2.67 3.78 
^'^C-leucine (prelabelled for 24 h) 
Control 897 1911» 2856® 
Leupeptin (70) 795 164P 2418'' 
Calpain Inhibitor I (93) 809 1285'' 2222" 
Calpain Inhibitor II (93) 802 1136'' 2053^ 
SEM^ 37 86 40 
Natural leucine (prelabelled on d 2 to 8) 
Control 13.97 24.06® 35.18® 
Leupeptin (70) 14.56 20.47'' 26.99'' 
Calpain Inhibitor I (93) 12.22 15.76® 21.07® 
Calpain Inhibitor n (93) 13.39 14.73® 17.72® 
SEM^ 0.578 0.987 1.041 
^Results are from 3 plates and are in /xg/ml for stable isotopes and cpm per 20 /xl sample 
for radioisotopes. Means without common letters in the superscripts vary significantly 
(P<0.05) from the other treatment means. Where no superscripting occurs, no significant 
difference exists. 
^Percentage decrease of isotope in the medium is used to calculate correction for utilization 
of label from the medium. 
^Pooled standard error of the means for each time point. 
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and 24 h were used in later experiments. The one hour time point allows for equilibrium 
of all soluble amino acid pools. This probably occurs within several minutes after the 
addition of fresh medium. Also shown are the ^H^-leucine and ^H-leucine utilization from 
the medium. The effects of leupeptin at 70 /xg/ml, and of calpain inhibitors I and n at 93 
fig/ml were examined. Significant (P < 0.05) treatment differences were obtained regardless 
of which isotope was used to prelabel the cells. Leupeptin significantly (P < 0.05) decreased 
release of natural leucine from the cells during the time from 1 to 24 h by 24 % and 1-^'^C-
leucine by 13 % when compared to the amount released from cells on the control plates. 
Again similar significant (P<0.05) differences were observed after correction with either 
^H-leucine or ^H^-leucine. Treatment of the cultures with both calpain inhibitors 
significantly (P<0.05) decreased release of both isotopes even further than treatment with 
leupeptin. In Table 7 the values obtained for natural and l-^'^C-leucine release were 
corrected as described in materials and methods by using uptake of either or 
leucine. Regardless of which isotope was used to make the correction, values obtained were 
similar and significant (P<0.05) differences remained. Figures 2 and 3 shows the curves 
obtained from plotting release of either natural leucine or l-^'^C-leucine corrected with ^H-
leucine and ^H^-leucine. The results obtained with either isotope, natural or 1-^'^C-leucine, 
and corrected with either release medium isotope, ^H-leucine and ^Hg-leucine gave 
essentially the same results with the same conclusions. 
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Table 7 Natural (^g/ml) and l-^'^C-leucine (cpm) corrected using and ^H-leucine 
utilization from the release medium.^ 
Isotope 8 Time (hr) 24 
Treatment (/ng inhibitor/ml) 
Natural leucine corrected using ^H-leucine 
Control 24.96^ 39.20^ 
Leupeptin (70) 22.34'' 31.60'' 
Calpain Inhibitor I (93) 16.25® 23.16'' 
Calpain Inhibitor H (93) 15.63° 20.07*^ 
SEM^ 0.700 0.949 
l-^'^C-leucine corrected using ^H-leucine 
Control 1978^ 3174^ 
Leupeptin (70) 1773^ 2782'' 
Calpain Inhibitor I (93) 1170'' 2444= 
Calpain Inhibitor II (93) 1351'' 2227^ 
SEM^ 70 41 
Natural leucine corrected using ^H^-leucine 
Control 26.78^ 42.80^ 
Leupeptin (70) 23.56'' 34.83'' 
Calpain Inhibitor I (93) 16.42'= 24.65^= 
Calpain Inhibitor II (93) 17.05'' 22.97" 
SEM^ 0.949 0.751 
1-^^C-leucine corrected using ^H^-leucine 
Control 2112® 3449® 
Leupeptin (70) 1862= 3046'' 
Calpain Inhibitor I (93) 1182'' 2708'= 
Calpain Inhibitor II (93) 1454'' 2353'' 
SEM2 92 62 
^Results are from 3 plates and are in jug/ml for stable isotopes and cpm per 20 fd sample 
for radioisotopes. Means with different superscripts vary significanfly (P<0.05) from the 
other treatment means. Where no superscripting occurs, no significant difference exists. 
All corrections for either ^H- or ^Hg-leucine were made as described in Materials and 
Methods. 
^Pooled standard error of the means for each time point. 
Figure 2 Correction of natural leucine release for utilization of either ^H-leucine (A) or 
%3-leucine (B). Cells were grown in medium containing natural leucine on d 2-8 
and on d 9 release medium containing ^ ^-leucine and trace amounts of ^H-Ieucine 
was used. Values (/tg/ml) obtained for natural leucine in the medium were then 
corrected for disappearance of release medium isotopes as described in Materials 
and Methods. 
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Figure 3 Correction of l-^'^C-leucine release for utilization of either ^H-leucine (A) or 
^Hg-leucine (B). Cells were grown in medium containing natural leucine on d 2-8 
and trace amounts of 1-^Meucine on d 8 for 24 h, then, on d 9 release medium 
containing ^^-leucine and trace amounts of ^H-leucine was used. Values (cpm) 
obtained for l-^'^C-leucine in the medium were then corrected for disappearance 
of release medium isotopes as described in Materials and Methods. 
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Dose responses to addition of calpain inhibitors I and n at 7, 23, 70, and 93 /tg/ml to 
the release medium: 
By growing the cells in natural leucine through day 8, all cellular proteins contained 
unlabelled leucine. Any potential isotope effects on protein synthesis and degradation have 
been eliminated during this time. This method of measuring natural leucine release into 
medium containing isotopic leucine greatly reduces the amount of expensive isotope needed 
to conduct the experiments, in addition to any biological advantage. Using natural leucine 
release into ^H^-leucine, 105 /tg/ml, containing release medium, and correcting for 
utilization using ^H^-leucine disappearance from the medium to correct for leucine 
utilization, the dose response to treatment with either calpain inhibitors I and n was 
examined. Table 8 shows the results of addition of calpain inhibitor I at concentrations of 
7, 23, 70, and 93 ^g/ml to the release medium on the natural leucine release from the cells 
and ^Hg-leucine utilization from the medium. Calpain inhibitor I significantly (P<0.05) 
decreased the release of natural leucine into the culture medium when compared to release 
in control plates by 55 to 73 % during the period from 1 to 24 h. No difference was 
observed between the treatment levels of calpain inhibitor I. In Table 9 correction for ^Hg-
leucine utilization is shown. Compared to natural leucine released into the culture medium 
in control plates from 1 to 24 h, calpain inhibitor I significantly (P <0.05) decreased release 
of natural leucine Arom 45 % at 7 ftg/ml to 63 % at 70 /xg/ml. There was a significant 
(P<0.05) response of dose in that 7 /lig/ml gave less decrease in release than the other 
calpain inhibitor I treatments. The same protocol was used to examine the dose response to 
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Table 8 Effect of calpain inhibitor I on release of natural leucine (/ig/ml) from cell proteins 
and on uptake of %3-leucine from the release medium.^ 
Time^ 
1 8 24 
Treatment^ Natural ^H^-leucine Natural ^Hg-leucine Natural ^Hg-leucine 
0 9.46 78.03 15.19* 63.46 22.03* 48.39 
7 9.51 74.58 11.08'' 62.58 15.05'' 47.42 
23 8.99 71.36 11.75'' 69.88 13.61'' 50.05 
70 9.68 81.86 11.23'' 71.58 13.14'' 55.73 
93 9.09 84.25 10.66'' 69.12 14.12'' 63.60 
SEM* 0.384 2.84 0.513 3.12 0.513 3.12 
^Data are the means of six culture plates (3 per week) and are fig leucine/ml. 
Means with different superscripts differ significantly (P<0.05). Where no 
superscripting occurs there are no differences. 
^Hours after release medium containing ^H2-leucine and the inhibitor were added. 
^Inhibitor concentration in the release medium (fcg/ml). 
'^Pooled standard error of the mean. 
to calpain inhibitor n with the results shown in Table 10. Calpain inhibitor II significantly 
(P<0.05) decreased proteolysis by 12, 62, 74, and 72 % with treatment levels of 7, 23, 70, 
and 93 ng/ml, respectively. After correction for ^H^-leucine utilization, the responses, 
shown in Table 11, are again similar to before the correction was made indicating no 
difference in uptake. Calpain inhibitor II continued to give significantly (P < 0.05) increased 
response at each level up to 70 ng/ml, which gave the same response as the 93 /ig/ml level. 
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Figure 4 shows a summary of the decrease in proteolysis, as measured by isotope appearance 
into the release medium, for the inhibitors used. 
Table 9 Natural leucine (/tg/ml) release from cultures treated with levels 
of calpain inhibitor 1 corrected for ^Hg-leucine 
utilization.^ 
Time^ 
Treatment level^ 8 24 
0 17.42* 28.47* 
7 12.57'' 19.94*' 
23 12.12'» 17.48": 
70 12.43*' 16.63° 
93 12.25*' 16.54* 
SEM* 0.51 0.66 
^Data are the means of six culture plates (3 per week) and are fig leucine/ml. 
Means with different superscripts differ significantly (P<0.05). Where no 
superscripting occurs there are no differences. Correction for ^H^-leucine 
utilization was done as described in Materials and Methods. 
^Hours after release medium containing ^H2-leucine and the inhibitor were added. 
^Inhibitor concentration in the release medium (fig/ml). 
'^Pooled standard error of the mean. 
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Table 10 Effect of calpain inhibitor II on release of natural leucine (^g/ml) from cell 
proteins and on uptake of %3-leucine from the release medium.^ 
Time^ 
1 8 24 
Treatment^ Natural ^H^-leucine Natural %3-leucine Natural ^H^-leucine 
0 6.87 56.52 12.12» 49.61 18.04» 35.90 
7 7.51 62.18 12.33* 53.03 17.32» 37.02 
23 8.37 63.04 9.95b 49.37 12.58^ 36.13 
70 7.53 63.78 9.05'' 56.74 10.44° 39.14 
93 7.39 66.00 8.24* 53.91 10.55* 43.47 
SEM"* 0.525 3.77 0.353 1.75 0.480 1.05 
^Data are the means of six culture plates (3 per week) and are fig leucine/ml. 
Means with different superscripts differ significantly (P<0.05). Where no 
superscripting occurs there are no differences. 
^Hours after release medium containing ^H2-leucine and the inhibitor were added. 
^Inhibitor concentration in the release medium (/*g/ml). 
'^Pooled standard error of the mean. 
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Table 11 Natural leucine (/tg/ml) release from cultures treated with levels 
of calpain inhibitor 11 corrected for ^H^-leucine 
utilization.^ 
Time^ 
Treatment level^ 8 24 
0 14.36^ 23.93* 
7 13.45^^ 22.78'' 
23 11.74b 17.28® 
70 10.29* 14.17d 
93 91.51° 13.41^ 
SEM^ 0.64 0.49 
^Data are the means of six culture plates (3 per week) and are /xg leucine/ml. 
Means without a common letter in the superscript differ significantly (P<0.05). 
Where no superscripting occurs there are no differences. Correction for 
^Hg-leucine utilization was done as described in Materials and Methods. 
^Hours after release medium containing ^H2-leucine and the inhibitor were added. 
^Inhibitor concentration in the release medium (/xg/ml). 
^Pooled standard error of the mean. 
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Figure 4 Decrease in proteolysis compared to controls after 24 h obtained with 
leupeptin and calpain inhibitors I and n as measured by release of 
leucine into culture medium. 
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DISCUSSION 
This paper has presented a new methodology for the study of protein degradation in 
embryonic primary cultures and has shown the response of primary chick embryonic muscle 
cell cultures to leupeptin and the calpain inhibitors I and U. Much research conducted with 
leupeptin shows inhibition of protein degradation to be variable in muscle cells and to range 
firom 10-54 Riebow and Young^ have reported that most of the effect of leupeptin is 
on the soluble cell proteins and that leupeptin has little effect on myofibrillar protein 
degradation. Libby and Goldberg^ have reported that in cultured embryonic chick muscle 
cells leupeptin decreased general protein degradation by 7-13 %. We obtained results of 13 
% inhibition with a 24 h radiolabel and 24 % with a 7 d stable isotope label. Given that the 
7 d label would be incorporated to a higher specific activity in many long half-life proteins 
in the cell, it is not surprising to see a greater response with the longer labelling method. 
In fact the longer the labelling period attainable, probably the truer the value obtained will 
be to representing general protein turnover. The calpain inhibitors I and n caused up to a 
74% decrease in proteolysis. Whether the calpain inhibitors were affecting a different set 
of proteases or whether they were just more biologically active was not determined. 
Leupeptin in solution, however, forms a hydrate and a carbinolamine.^^ Thus, only a small 
amount of the leupeptin in solution may be in the free aldehyde or active form at any one 
time. Presumably the calpain inhibitors I and 11 are all in the free aldehyde or active form 
when in solution. 
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One inherent disadvantage to the use of radioisotopes is the complications involved 
with compound identification. To avoid this, nonrecyclable tracers such as 3-methyl-
histidine and nonmetabolizable tracers such as tyrosine have been used to label cell proteins. 
Stable isotope measurement of proteolysis in cell cultures offers a simple one step analysis 
of the culture medium for the specific compound of interest. In contrast to radioisotopes, 
quantification of specific compounds is a one step operation using GC/MS analysis. 
Previous methodologies have involved duplicate plates to obtain results, which are expressed 
on a crude protein basis. In our methodology we have used utilization of isotope from the 
medium to correct for the small differences between plates, and statistical methods to remove 
other variable components as week to week variation. By labelling essentially all the leucine 
in the cell protein we also eliminate any variance found in label specific activity in the 
proteins. 
Although our method of correction is able to correct for label loss from the medium 
due to protein synthesis or leucine oxidation, leucine released by protein degradation and 
immediately reutilized for protein synthesis can not be corrected for using this methodology. 
The addition of cycloheximide to prevent intracellular reutilization of the leucine tracer is 
commonly used^^ and was evaluated in separate experiments. The results of those 
experiments indicated that cycloheximide had an effect on protein degradation.^^ 
The stable isotope labelling protocols showed more consistent and earlier differences 
among the various inhibitor treatments than did the radioisotopes. The labelling protocols 
used in these experiments resulted in the stable isotope and natural leucine attaining a much 
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higher labelling rate due to the concentrations used and the labelling times involved. Long 
term labelling with radioisotopes is not generally used because of the possibility of the 
isotope being incorporated into many cellular components. This makes separation and 
counting of the particular compounds increasingly difficult as the labelling time with 
radioisotopes increases. Labelling to a high and constant specific activity is then difficult 
because of the amount and times necessary to achieve this. On the other hand, growing the 
cells in natural leucine, "labels" all of the cellular proteins at every leucine. Thus every 
protein is at 100 % specific label activity therefore eliminating any chance that the results 
may be prejudiced through the mechanism by which proteins are chosen to be broken down. 
In summary the final method that we have described utilizes no radioisotopes and 
therefore does not require all of the elaborate procedures involved in working with 
radioactivity. The use of this labelling method allows for one step GC/MS analysis of the 
label and provides a valuable new tool for analysis of the effect of added compounds on 
protein degradation. 
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ABSTRACT 
In in vitro studies of protein turnover, cycloheximide has commonly been used to halt 
protein synthesis, thus eliminating the problem associated with tracer reutilization in protein 
turnover studies. This methodology assumes that at least during the time course of the 
experiment, cycloheximide's effect on protein degradation is minimal or nonexistent. Since 
it has been shown that cycloheximide can influence protein degradation in certain cells and 
tissues, the following experiments were performed to determine the effect of cycloheximide 
on protein turnover in embryonic chick primary skeletal muscle cell cultures. Myoblasts 
from leg and thigh muscles were removed and plated on 60-mm collagen-coated plates (5.5 
X 10® cells/plate). Cultures were grown for 7 days in 3 ml per plate of Dulbecco's MEM, 
supplemented to contain all 20 amino acids, 10% horse serum, 2.5% embryo extract, 50 lU 
penicillin G/lOO ml, and 1% Fungizone. Cultures were grown in a 5% CO2 atmosphere at 
37'C and 90% humidity, and the culture medium was changed every 24 h. On days 5 and 
6, medium containing 5 X 10"^ M cytosine-/3-D-arabinofuranoside was fed to kill any 
dividing cells and leave a relatively pure culture of fused, nondividing myotubes. On day 
8, cultures were rinsed with phosphate buffered saline, and fresh medium containing 0.375 
mM cycloheximide was added. In the first experiments cells were fed medium containing 
1/2 the leucine as [5,5,5]-^H3-leucine for d 2-8 and tracer amounts of l-^'^C-leucine were 
added for 24 h on d 8. Release medium contained natural and ^H-leucine. During the 
release period, medium from duplicate plates was precipitated to correct for differences in 
precipitable counts of ^^C-leucine between the control and cycloheximide treated plates. 
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After 24 h, there was a significant (P<0.05) 11 % decrease in protein degradation, as 
measured by appearance of ^^C-leucine dpm in the medium of cycloheximide treated plates 
when compared to control ^'^C-leucine dpm. However, we expected the value to be larger 
with cycloheximide, since there was little intracellular reutilization of tracer. With 
cycloheximide treatment ^H^-leucine in the release medium showed a 6 % decrease when 
compared to controls (P< 0.053). In the second set of experiments conducted all labelling 
was done with stable isotopes. On d 2-7 the medium contained all leucine as 1-^^C-leucine 
and for d 8 all leucine as natural to label short half-life proteins with natural leucine and long 
half-life proteins with ^^C-leucine. Corrected for extracellular reutilization both the short 
and long half-life labels showed a significant (P<O.OS) decrease in protein degradation of 
48 % after 24 h. Although with the short term label the actual means of the amount in the 
medium were not significantly different at 8 h, the change in natural leucine in the medium 
was significantly (P<0.05) less by 27 % with cycloheximide treatment from 1 to 8 h. The 
long term label showed a significant (P<0.05) decrease of 18 % with cycloheximide 
treatment from 1 to 8 h. It would appear that at first cycloheximide was affecting the 
degradation of short half life proteins more than that of long half life proteins. These results 
indicate that cycloheximide's effect on the cells occurs quickly and that measurement of 
absolute rates of protein degradation can not be attained with the use of cycloheximide in 
muscle cell culture systems. 
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INTRODUCTION 
Understanding the factors that regulate animal growth requires knowledge of protein 
metabolism, in particular muscle protein metabolism. Determination of the effects of 
hormones, protease inhibitors, and other compounds on tissue growth requires measurement 
of the rates of protein synthesis and degradation. Experimental models, such as muscle 
strips,^ isolated muscles,^ and cell cultures^ have been widely used to measure the effects 
of the compounds on protein metabolism. While protein synthesis rates are relatively easy 
to determine by measuring the rate of incorporation of a labelled amino acid into protein, 
protein degradative rates are more difficult to measure. 
Although many methods may be used to determine protein degradation, the absolute 
rate of degradation is difficult to determine. One method commonly used is the pulse chase 
technique, where a labelled amino acid is used to label cell proteins, followed by 
measurement of either release^ of the label or decrease of label in the protein.'* Errors in 
measurement made with this technique are caused by reutilization or metabolism of the tracer 
label that is being used. One way to overcome this problem is to choose a non-recycled, 
non-metabolized compound to measure the rate of protein degradation, such as 3-
methylhistidine. 3-methylhistidine, found in actin^ and fast twitch myosin®, provides a way 
to measure the degradation rate of myofibrillar proteins.^ While the 3-methyl-histidine 
method has provided important data, especially in vivo, 3-methyl-histidine only indicates 
myofibril breakdown and can not be used as an indication of cytosolic protein degradation. 
Skeletal muscle is from 15-23 % protein and of this only 52-56 % is myofibrillar proteins,® 
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therefore, cytosolic protein degradation is very important in determining the energetics of 
protein utilization. An alternative is to block protein synthesis so reutilization of labelled 
amino acids released from prelabelled proteins is impossible.^ With this methodology the 
only concerns would be with metabolism of the label as recycling of the label is halted. 
Commonly cycloheximide has been used to block protein synthesis in most tissue^ and cell 
culture systems.For example, Bulks et. al.^ used 0.5 mM cycloheximide in the 
medium to block protein synthesis in rat diaphragm tissue. Cycloheximide acts to prevent 
peptide chain elongation during protein synthesis and will also cause polysome 
disaggregation.^^ A major assumption made in these studies is that cycloheximide has no 
effect on protein degradation during the time course of the experiment. This assumption 
may, however, be erroneous in that some investigators have reported a need for protein 
synthesis to support higher than normal rates of degradation induced in nutritionally deprived 
hepatoma cells^^ and in hepatoma cells in serum free medium. In both of these cases, 
the addition of cycloheximide to the cultures resulted in reduction of the induced higher than 
normal protein degradation to approximately normal basal levels of protein degradation found 
in cells grown with adequate nutrition and serum factors. While this is not conclusive proof 
that cycloheximide affects normal protein degradation, it does show that continuing protein 
synthesis, presumably of proteases in particular, is necessary to sustain at least some levels 
of protein degradation. This effect has also been shown for skeletal muscle cell cultures 
deprived of serum and embryo extract. 
One would expect that the addition of cycloheximide to a system measuring protein 
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degradation, would cause an increase in label release from protein by eliminating 
reutilization. Thus, the 'absolute' rate of protein degradation measured with cycloheximide 
should be of a higher magnitude than if cycloheximide was not included. In cultured fetal 
mouse hearts cycloheximide has been shown to decrease protein degradation by 18 % overall 
and cathq)sin D activity by 49 %. After 48 h, cathepsin D activity was decreased by 61 % 
and overall degradation, as measured by ^H-phenylalanine release, was decreased by 31 
A report that inhibition can start as early as 15-20 minutes after cycloheximide 
addition could render the main assumption with cycloheximide invalid. One hypothesis 
concerning mechanisms of intracellular proteolysis is that basal protein degradation occurs 
via three routes, a complementary lysosomal, an autophagic supplementary induced 
lysosomal, and a neutral mechanism not lysosome associated. The effect of 
cycloheximide has been proposed to first affect the lysosomal pathways and then more slowly 
the neutral mechanism. The autophagic supplementary acidic pathway is probably controlled 
by serum factors that cause synthesis of suppressor proteins. Nonetheless, measurement 
of degradation rates in the presence of cycloheximide remains widely used in muscle model 
systems. 
We have developed a method for using stable isotopes to measure proteolysis in 
embryonic chick primary skeletal muscle cell cultures. Stable isotope labelled amino acids 
have been shown to be effective in studying protein degradation in primary chick muscle cell 
cultures.^^ Initial studies suggested that cycloheximide affected the rate of protein 
degradation in muscle cell cultures. Thus, we applied this methodology to study the relative 
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effect that cycloheximide might have on protein turnover of both shorter and longer half-life 
proteins by using different stable isotopes for different labelling times. 
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MATERIALS AND METHODS 
Muscle cell cultures: 
12-d incubated specific pathogen free eggs from a layer strain of chicken were 
obtained firom Hy-Vac Laboratory Eggs (Cowrie, L\). Myogenic cells from the legs of the 
embryos were separated by mechanical dissociation and planted at the rate of 5.5 X 10^ cells 
per 60 mm collagen coated culture plate.^^ Medium for general muscle cell culture 
contained 500 ml Dulbecco's modified eagle medium, supplemented to contain all 20 amino 
acids, (DMEM deficient, low glucose, powdered form, Sigma Chemical Co., St. Louis, 
MO), 60 ml horse serum (Gibco), 15 ml embryo extract, 6 ml of penicillin G solution 
(resulting in 50 lU/ml of media, Gibco), and 3.25 ml Fungizone (resulting in 1.39 ng 
amphotericin B/ml in the media, Sigma, St. Louis, MO). Cultures were grown for 7 days 
in 3 ml medium per plate in a 5% CO2 atmosphere at 37'C and 90% humidity, and the 
culture medium was changed every 24 h. On days 5 and 6, medium containing 5 X 10'^ M 
cytosine-iS-D-arabinofuranoside was fed to kill any dividing cells and leave a relatively pure 
culture of fused, nondividing myotubes. On day 8, cultures were rinsed once with 
phosphate buffered saline (3.3 mM NaH2P0^, 6.7 mM Na2HP0^, and 150 mM NaCl, pH 
7.0), and fresh medium was added containing 0.375 mM cycloheximide (Sigma Chemical 
Co., St. Louis, MO) and in which all of the leucine was replaced by a different isotope of 
leucine than what had been previously used for labelling purposes. Control plates received 
the same medium without cycloheximide. During the next 24 h, measurement of the various 
isotopes of leucine released into the medium was used as an indication of relative proteolysis. 
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Three plates per treatment were used for each experiment. Two replicate experiments were 
conducted for each set of experiments. 
Initial studies found that 0.375 mM cycloheximide blocked the uptake of l-^'^C-
leucine into the trichloroacetic acid precipitable fraction of muscle cell protein by 95 ±3 % 
(n=10, control vs cycloheximide-treated cultures). After the labelling period on day 7 of 
culture, culture plates were rinsed twice with PBS containing 1 mM leucine. The PBS 
solution was allowed to sit on the plates for 10 min for each rinse. For precipitation cells 
were dissolved in 2 ml 3 N NaOH and allowed to sit for 1 h or until dissolved. A sample 
(750 /tl) was taken and to this was added an equal volume of 40 % TCA. This mixture was 
vortexed and spun at 10000 g in a microcentrifuge. The resulting pellet was washed with 
TCA and then suspended in 1.5 ml 3 N NaOH and sampled for counting. This level of 
cycloheximide did not visibly affect the cells as judged microscopically by their ability to 
contract and remain adhered to the culture plates. 
Stable isotope labeling: 
[5,5,5]-%3-leucineand 1-^^C-leucine (Tracer Technologies Inc., Newton, MA) were 
utilized to label the primary cell cultures for different time periods as described in results. 
^Hg-leucine was added as one half of the normal leucine amount, 105 jug/ml, in the first set 
of experiments and ^^C-leucine was added as all of the 105 ng leucine/ml in the medium in 
the second set of experiments. Long-term labelling was done beginning on d 2, before 
significant fusion had occurred, and continuing until the release medium was added or until 
24 h before addition of the release medium depending on the experimental protocol. The 
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long-term labelling labelled all cell proteins to the same extent, since this was the only 
leucine available to the cells. Short-term labelling was for the 24 h period prior to 
measurement. The label added for this purpose would label to a greater proportion those 
proteins with shorter half lives. 
Radioisotope labeling: 
For 1-^^C-leucine labelling, 2500 /tCi of 1-^^C-leucine (342 mCi/mM, Amersham, 
Arlington Heights, IL) was dried under nitrogen gas, diluted to 2 ml volume with water, and 
sterilized by filtration. Labelling of the cell cultures with ^'^C-leucine was started 24 hours 
before measurement with the addition of 6 /il (approx. S /tCi) of the 1-^^C-leucine solution 
to each plate. 
To determine loss of leucine from the medium used to measure release of label from 
prelabelled protein (release medium) 5000 nCi of ^H-leucine (approx. 50 mCi/mM, 
Amersham, Arlington Heights, IL) was dried under nitrogen gas, diluted to a volume of 2.5 
ml with water, and sterilized by nitration. The ^H-leucine was added directly to the release 
medium at the start of the measurement period at the rate of 20 fil (approx. 2.7 nCi) per 10 
ml of release medium for each treatment and each plate received 3.2 ml release medium. 
Collection and processing of samples: 
At the end of the labeling period the medium was removed, the cells were washed 
once with warm PBS and the release medium added. 20 fd samples of media were taken for 
gas chromatography/mass spectrometry (GC/MS) measurement and scintillation counting 
(Beckman LS1700 liquid scintillation counter, Fullerton, CA) at various times during the 
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release period depending on the week's experiment. For scintillation counting, the 20-/tl 
media samples were taken at the specified times (either 2, 8, and 24 h or 1, 8, and 24 h 
depending on the experiment as described in results) and deposited directly into scintillation 
vials and 2 ml of cocktail (Scintiverse BD, Fisher, Pittsburg, PA) was immediately added. 
Samples for GC/MS analysis were simultaneously taken, immediately frozen at -20'C, and 
dried as soon as possible at 70*C under nitrogen gas. Samples were then derivatized with 
100 /il acetylnitrile plus 100 nl N~methyl-N-(t-butyl-chlorosilane)-trifluoroacetamide 
containing 1% /-butyldimethylchlorosilane (Regis Chemical Company, Morton Grove, 
IL)^\ Natural (unlabelled) and ^Hg-leucine were measured at 302 and 305 AMU, 
respectively, by using a GC/MS system (Hewlett-Packard 5970A). 
Some medium samples were taken from cell cultures to determine the trichloroacetic 
acid (TCA) precipitable cpm. For TCA precipitation 100 nl media samples were taken, 
generally from a duplicate set of plates, to which was added 100 /xl 20 % cold TCA. 
Samples were then vortexed and centrifuged in a microcentrifuge at approximately 10,OCX) 
g. The resulting pellet was rinsed with fresh TCA and then dissolved in 400 /*1 of 3 N 
NaOH. Data was then corrected using the determined % TCA precipitable counts. At 24 
h media samples from cycloheximide treated and control plates were centrifuged at 1,000 g 
for 15 m and then sampled to determine if any cell fragments from cycloheximide treated 
plates were contributing to the higher raw dpm seen. There were no differences between 
samples taken in the normal sampling manner and those taken after media centrifugation. 
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Statistics and calculations: 
Differences between treatments were assessed by using analysis of variance with the 
General Linear Models procedure of SAS (SAS Institute Inc., Gary, NC). Individual 
treatment means were compared by using the least squares means calculations in the case of 
unequal replication and Duncan's multiple range test for means where cell sizes were equal. 
Experiments were repeated in each of two weeks. Week to week variation was removed in 
the model by using experiment number as a covariate. Therefore a model of the parameters 
estimated would be: Yjj|j= n + j8T| + aWj + Erroryj^, where Yijjj=observation, 
/x=population mean, /3T|=treatment effect, aWj =week to week variation, and Errorijij=lack 
of fit for observation Yy]^. By removing the variation due to experiment statistically, instead 
of converting all the data to a common unit, the power of our test was increased. 
Loss of either ^H-leucine or ^H^-leucine from the release medium was used to 
determine loss of leucine from the release medium during the measurement period (due to 
protein synthesis or oxidation of leucine). Values for release of label from cell protein were 
corrected as follows: 
corrected 8 h =0.5*(V^4-Vg)*% decreasei.g+Vg; 
corrected 24 h=0.5*(Vi+Vg)*% decreasei.8+0.5*(Vg+V24)*% decreaseg.24 +V24; 
where: 
Vi= value,  ei ther dpm or / tg/ml,  for labell ing isotope released into the medium at  1 h,  
Vg=value, either dpm or fig/ml, for labelling isotope released into the medium at 8 h, 
V24=value, either dpm or /ig/ml, for labelling isotope released into the medium at 24 h, 
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% decreasei.8=loss of ^H- or ^H^-leucine from the release medium from 1 to 8 h, 
and % decreaseg.24=loss of or %3-leucine from the release medium from 8 to 24 h. 
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RESULTS 
Tables 1 and 2 contain data simultaneously obtained from the same cell cultures. 
The cells had been grown with a ^H^-leucine label for days 2-8 and for 24 h on day 8 with 
1-^'^C-leucine. Table 1 shows that cycloheximide increased (P<0.05) the release of l-^'^C-
leucine, as indicated by higher ^^*0 dpm in the release medium, at both 8 and 24 h when 
compared with the value from the control plates. This was to be expected if reutilization 
was blocked by the cycloheximide. After correction for ^H-leucine utilization, there was still 
a significant (P<0.05) increase in dpm released into the medium in the cycloheximide 
treated plates at both 8 and 24 h. Media samples were TCA precipitated to remove label in 
protein in the medium due to secretion of labelled proteins from the cells. Final correction 
for TCA precipitable dpm shows a significant (P<0.05) 11.4 % decrease in release of ^'^C-
leucine from cycloheximide-treated plates when compared to that released from control 
plates. In Table 2 release of ^Hg-leucine from the cycloheximide-treated cells was increased 
significantly (P<O.OS) before correction for utilization, which again was expected. 
Correction for precipitable counts is not necessary with the %3-leucine label as only free 
isotopic leucine is measured with GC-MS analysis. However, after correction for ^H-leucine 
utilization, cycloheximide decreased release at the 24 h point by 6 % (P<0.053). 
Because of the overlap in the labelling times of the two labels used, the ^Hg-leucine 
was also labelling that portion of short half-life protein that was labelled with l-^'^C-leucine. 
Given the magnitude of the extra corrections needed with the radioisotope of leucine, the 
next experiments were designed to use only stable isotopes of leucine and to separate the 
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Table 1 l-^'^C-leucine (dpm) release from cells and ^H-leucine (dpm) utilization from the 
medium with 0.375 mM cycloheximide in the release medium.^ 
Isotope^ Time (hr) 
Treatment 18 24 
^H-leucine (added to the release medium at time 0) 
Control 10890 8566® 6139® 
Cycloheximide 11246 11244^ 11180^ 
SEM^ 145 103 131 
l-^'^C-leucine (prelabelled for 24 h) 
Control 949 2006® 2859® 
Cycloheximide 1040 2595^ 4603^ 
SEM^ 36 41 82 
l-^'^C-leucine corrected for ^H-leucine utilization'^ 
Control 2321® 3861® 
Cycloheximide 2595*^ 4623'' 
SEM^ 44 69 
l-^'^C-leucine corrected for ^H-leucine utilization and TCA precipitable counts.^ 
Control 879 2098 3414® 
Cycloheximide 950 2068 3197^^ 
SEM^ 32 42 40 
^Results are the means of dpm per 20 lû samples from 6 plates. Means with different 
superscripts vary significantly (P<0.05) from the other treatment mean. Where no 
superscripting occurs, no significant difference exists. 
^1-'^C-leucine was used to prelabel the cells for 24 h. At time 0, medium containing 
^H-leucine both with and without cycloheximide was added to the cultures. 
^Pooled standard error of the means for each time point. 
'^Corrected for disappearance of the isotope from the medium by reutilization 
using the ^H-leucine as described in Materials and Methods. 
^Corrected for ^H-leucine utilization and TCA precipitable counts as described in Materials 
and Methods. 
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Table 2 ^Hg-leucine labelling cell cultures for days 2-8 and the effects of 
0.375 mM cycloheximide on release of label. ^  
Treatment 1 
Time (hr) 
8 24 
^Hg-Ieucine (prelabelled on d 2-8) 
Cycloheximide 1.161 
SEM^ 0.252 
Control 1.445 2.998 
3.065 
0.219 
4.529= 
5.280"' 
0.206 
^Hg-leucine corrected for ^H-leucine utilization^ 
Control 
Cycloheximide 
SEM^ 
3.478 
3.227 
0.249 
6.080 
5.525 
0.189 
^Results are the means of from 6 plates in ^g/ml. Means with different superscripts vary 
significantly (P<0.05) from the other treatment mean. Where no superscripting occurs, no 
significant difference exists. 
^Pooled standard error of the means for each time point. 
^Corrected for disappearance of the isotope from the medium by reutilization 
using the ^H-leucine as described in Materials and Methods. 
labelling such that a separate and distinct isotope was used as the only leucine available for 
the 24 h labelling period before measurement began. This also allows direct determination 
of the amount of leucine with each label released. 
Table 3 shows the results from the use of stable isotopes of leucine for both long and 
short term labelling. ^H^-leucine, used in the release medium shows, a decline of 65% in 
the medium fed to the control plates and only a 14.5 % decrease in the medium fed to the 
cycloheximide treated plates. This difference in utilization of leucine from the medium 
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between the two groups was probably primarily due to protein synthesis, as experiments 
showed the level of cycloheximide used blocked incorporation of label into protein by 95 %. 
Therefore, the decrease observed in the cycloheximide-treated cultures was probably due to 
leucine oxidation. Total leucine remained about constant over the 24 h period in control 
plate medium, indicating that during the time span of the experiment the control plates were 
in a state of approximate nitrogen balance. Total leucine increased in cycloheximide-treated 
plate medium as expected, because if protein synthesis was blocked with cycloheximide, 
protein degradation should result in an increase in the amount of leucine in the medium. 
Significantly more (P<O.OS) short term label, natural leucine was released from the 
cycloheximide treated cultures at 1 and 8 h post treatment, but there was no difference at 24 
h. With correction for loss of ^H^-leucine from the release medium the absolute difference 
disappeared at 8 h, however, there was a significant (P<0.05) 27 % decrease in the amount 
released from 1 to 8 h. At 24 h the control plates showed significantly more release 
indicating that cycloheximide treatment resulted in a 48% decrease in degradation of proteins 
synthesized during the 24 h labelling period. The differences for the long term label, 1-^^C-
leucine, essentially paralleled those of the short term label. No difference existed at 1 or 8 
h and significantly (P<O.OS) more was released from the control group at 24 h. Again if 
these data are corrected for uptake at the 8 and 24 h times, there was significantly (P < 0.05) 
more 1-^^C-leucine in the medium of the control plates at both times. Cycloheximide 
decreased release of long term label by 18 % and 48 % at 8 and 24 h, respectively. 
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Table 3 Stable isotope labelling of chick primary muscle cell cultures and the effect of 
cycloheximide on 24 h and 2-6 d labels.^ 
Isotope Time (hr) 
Treatment 1 8 24 
Natural (prelabelled 24 h) 
Control 4.73» 8.02'' 10.08 
Cycloheximide 5.63'' 8.93'' 10.61 
SEM2 0.276 0.093 0.417 
Natural corrected for utilization of ^H^-leucin^ 
Control 10.08 16.46» 
Cycloheximide 9.54 11.73'' 
SEM^ 0.372 0.349 
1-^^C-leucine (prelabelled on d 2-7) 
Control 1.09 3.67 6.98» 
Cycloheximide 1.03 3.57 5.43'' 
SEM^ 0.098 0.127 0.250 
1-^^C-leucine corrected for utilization of ^H^-leucine^ 
Control 4.42» 10.30» 
Cycloheximide 3.76'' 5.84'' 
SEM^ 0.153 0.217 
^Hg-leucine 
Control 16.22 10.94» 5.68» 
Cycloheximide 17.68 16.13'' 15.12'' 
SEM^ 0.746 0.301 0.431 
Total leucine 
Control 22.04 22.63» 22.74» 
Cycloheximide 24.33 28.63"' 31.16'' 
SEM2 0.995 0.323 1.043 
'Results are from 6 plates, 3 in each of two weeks. Means with different superscripts vary 
significantly (P<0.05) from the other treatment mean. Where no superscripting occurs, 
no significant difference exists. 
^Pooled standard error of the means for each time point. 
^Corrected for disappearance of the isotope from the medium by reutilization 
using the ^H^^-leucine as described in Materials and Methods. 
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Therefore, while the effect at 24 h was similar, it would appear that cycloheximide's effect 
on the short term label was greater during the first 8 h than that for the long term label. 
Corrected values for release of short and long term label and the utilization of 
leucine from the medium are shown graphically in Figure 1. From the figure it can be seen 
that cycloheximide's effect begins rather quickly and reaches significance (P<0.05) by 8 h. 
THe release of both labels, as indicated by the slopes of the lines is less during both the 1-8 
and 8-24 h time periods with cycloheximide treatment. 
Figure 1 Effects of cycloheximide on protein degradation in primary chick skeletal muscle 
cell cultures. A) release of 24 h label, natural leucine, and 2-7 d label, 1-^^C-
leucine, from 8 d old cultures corrected for utilization of label from the medium 
as described in Materials and Methods B) utilization of ^H^-leucine from the 
release medium. As can be seen from the slopes of the release of label from 
cycloheximide-treated cultures, there was a slower rate of release of both labels 
beginning as early as the 1-8 h time period. 
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DISCUSSION 
Results of this study demonstrate that cycloheximide affects the rate of protein 
degradation of both long and short half life proteins in primary embryonic chick skeletal 
muscle cell cultures growing in complete medium. This effect was most clearly seen in the 
experiments done using all stable isotope labelling methods, due to the fact that, with stable 
isotopes, leucine is measured directly by GC/MS. With radioisotope labelling, it is 
necessary to TCA precipitate the media samples to correct for labelled proteins in the 
medium. Even with this correction, it cannot be assured that all of the label measured is 
free leucine. The purpose for adding cycloheximide is to block reutilization of amino acids 
from protein degradation after they enter the intracellular pool.^'^ Our results show that the 
use of cycloheximide to obtain absolute rates of protein degradation in cell cultures is 
invalid, because cycloheximide alters the protein degradative rate. 
Analysis of protein degradation by measurement of release of labelled leucine into the 
culture medium allows sampling of the same culture plate at different time points. This 
method assumes that the rate of appearance of labelled leucine in the culture medium reflects 
the rate of release of labelled leucine from cellular proteins, i.e. that changes in the amount 
of leucine in the intracellular pool are reflected by changes in the culture medium. It has 
been reported that at leucine levels of 0.5 mM and greater, the specific activity of a label 
in the medium pool is similar to the specific activity found in the intracellular pools.^^ In 
Chinese hamster ovary cell leucine levels comparable to the levels found in primary muscle 
cell culture, 0.8 mM, result in 95% of t-RNA charging from medium pools of leucine.^ 
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This would allow comparisons using measurements made of label pools in the medium to be 
used to make relative comparisons between various treatments applied to the cultures that 
might affect leucine metabolism. Correction for utilization from the culture medium once 
the label reaches that pool is easily made, however correcting for the reutilization from the 
cellular pool is a very time consuming process. Our labelling method used either or 
^Hg-leucine, added to the release medium, to correct for uptake of leucine during the release 
period. Again, assuming equilibration of all labels in the medium pool, this should provide 
a valid method to correct for uptake. This method cannot, however, distinguish between 
leucine used for protein synthesis and leucine used for oxidation, but this should not affect 
the degradation measurements. 
If addition of cycloheximide to block protein synthesis provided a valid method for 
measuring absolute rates of protein degradation, then the rate of protein degradation seen 
with cycloheximide should be greater than that seen in non-treated control plates. We 
consistently observed a decrease in degradation in response to cycloheximide. This effect 
was evident early in the measurement period and could greatly affect measurements on 
longer half life myofibrillar proteins. While it is often acknowledged that cycloheximide 
decreases the rate of protein degradation, it would seem that this is largely ignored as 
unimportant, particularly in studies with muscle strips. Cycloheximide is often used to 
determine the net rate of proteolysis without having to measure specific activity of the t-RNA 
precursor pool and determining protein synthesis. However, as our understanding of 
protein degradation and specifically our understanding of the signals that control degradation 
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become more clear, the potential for errors from the confounding effect of cycloheximide 
may well increase. 
The mechanism for the effect of cycloheximide on protein degradation is not known. 
It has been theorized that cycloheximide's effect on protein turnover is similar to the effect 
of serum factors and insulin in that all suppress synthesis of an enhancer peptide or 
protein. Woodside^^ has suggested that the effect of cycloheximide on protein degradation 
may be the result of changes in intracellular amino acid pools. This was suggested after he 
saw increased gluconeogenesis and urea production in perfused rat liver. 
We have also shown that cycloheximide decreases protein degradation of shorter half 
life proteins more than longer half life proteins during the first 8 h. If these differences are 
the average of many hundreds or thousands of proteins in each class, then cycloheximide 
may totally stop degradation of some, while enhancing degradation of others. Knowles and 
Ballard^'* proposed that, in Reuber H3S hepatoma cells, cycloheximide inactivates one 
pathway for degradation, since cycloheximide decreases normal protein degradation by up 
to 32 % and aberrant protein degradation by only 9 %. They also obtained similar results 
with puromycin and insulin. Their results indicate that certain pathways may be more 
susceptible to the lack of protein synthesis. From our data on muscle cell cultures, 
calculation of the relative amounts of leucine released from the labelled proteins shows that 
only 44-50 % of label released comes from long term labelling. Such long term labelling 
studies can only be accomplished easily with the use of stable isotopes. Typical pulse chase 
labelling uses a 3-16 h labelling period.'^'^ With such a short labelling time, specific activity 
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of label in the long half life proteins would be much less than for shorter half life proteins. 
Thus, measurement of relise of label would prejudice results towards the short half life 
proteins. Further studies using different labelling times with stable isotopes could be useful 
in determining relative degradative rates for different class half life proteins. 
In summary the results shown herein demonstrate that cycloheximide can affect 
protein degradation rather quickly, and that the effect seems to be more pronounced with 
time. As research continues and more specific pathways of protein degradation are 
examined, the use of cycloheximide may not be feasible as the effects of the treatment may 
be masked. In fact, the use of cycloheximide to determine absolute rates of protein seems 
invalid, because cycloheximide affects protein degradation. 
85 
ACKNOWLEDGMENTS 
The authors of the paper wish to express their thanks to Janet Stephenson for her 
expertise in growing the cell cultures. 
86 
REFERENCES 
1. Libby, P., and Goldberg, A. L. (1978). Leupeptin, a protease inhibitor, decreases 
protein degradation in normal and diseased muscles. Science 199:534-536 
2. Sonka, I., Takahashi, S., Kadowaki, M., Noguchi, T., and Naito, H. (1984). Effects 
of bestatin and leupeptin on protein degradation in perfused rat hindquarters: accumulation 
of acid soluble peptides in muscle during bestatin perfusion. Agric. Biol. Chem. 48:2763-
2769 
3. Young, R. B., Moriarity, D. M., McGee, C. E., Farrar, W. R., and Richter, H. E. 
(1990). Protein metabolism in chicken muscle cell cultures treated with climaterol. J. Anim. 
Sci. 68:1158-1169 
4. Riebow, J. P., and Young, R. B. (1980). Effect of leupeptin on protein turnover in 
normal and dystrophic chicken skeletal muscle cells in culture. Biochem. Med. 23:316-323 
5. Asatoor, A. M., and Armstrong. (1967). 3-methylhistidine, a component of actin. 
Biochem. Biophys. Res. Commun. 26:168-174 
6. Johnson, P. C., Harris, C. I., and Perry, S. V. (1967). 3-methylhistidine in actin and 
other muscle proteins. Biochem. J. 105:361-370 
7. Hillgertner, F. B., Williams, A. S., Flanders, J. A., Morin, D., and Hansen, R. J. 
(1981). Myofibrillar protein degradation in the chicken 3-methylhistidine release in vivo and 
in vitro in normal and genetically muscular-dystrophic chickens. Biochem. J. 196:591-601 
8. Coll, D. E., Stromer, M. H., and Robson, R. M. (1977). Skeletal muscle in Duke's 
physiology of domestic animals 9th ed. ed. Swenson, M. J. Ch 39. Cornell University Press, 
Ithaca, NY 
9. Fulks, R. M., Li, J. B., and Goldberg, A. L. (1975). Effects of insulin, glucose, and 
amino acids on protein turnover in rat diaphragm. J. Biol. Chem. 250:290-298 
10. Vandenburgh, H., and Kaufman, S. (1980). Protein degradation in embryonic skeletal 
muscle: effect of medium, cell type, inhibitors, and passive stretch. J. Biol. Chem. 
255:5826-5833 
11. Knowles, S. E., and Ballard, F. J. (1976). Selective control of the degradation of 
normal and aberrant proteins in reuber H35 hepatoma cells. Biochem. J. 156:609-617 
87 
12. Baliga, B. S., Pronczuk, A. W., and Munro, H. N. (1969). Mechanism of 
cycloheximide inhibition of protein synthesis in a cell-free system prepared from rat liver. 
J. Biol. Chem. 244:4480-4489 
13. Auricchio, F., Martin, D. Jr., and Tomkins, G. (1969). Control of degradation and 
synthesis of induced tyrosine aminotransferase studied in hepatoma cells in culture. Nature 
224:806-808 
14. Epstein, D,, Elias-Bishko, S., and Hershko, A. (1975). Requirement for protein 
synthesis in the regulation of protein breakdown in cultured hepatoma cells. Biochem. 
14:5199-5204 
15. Wildenthal, K., and Griffen, E. E. (1976). Reduction by cycloheximide of lysosomal 
proteolytic enzyme activity and rate of protein degradation in organ-cultured hearts. Biochim. 
et Biophys. Acta. 444:518-524 
16. Woodside, K. H. (1976). Effects of cycloheximide on protein degradation and 
gluconeogenesis in the perfused rat liver. Biochim. Biophys. Acta. 421:70-79 
17. Amenta, J. S., and Brocher, S. C. (1981). Minireview: mechanisms of protein 
turnover in cultured cells. Life Sci. 28:1195-1208 
18. McGrath, J. A., and Goldspink, D. F. (1982). Glucocorticoid action on protein 
synthesis and protein breakdown in isolated skeletal muscles. Biochem. J. 206:641-645 
19. Preedy, V. R., Smith, D. M., Kearney, N. F., and Sugden, P. H. (1984). Rates of 
protein turnover in vivo and in vitro in ventricular muscle of hearts from fed and starved 
rats. Biochem. J. 222:395-400 
20. Fuller, J. C., Jr., Link, G. A., Nissen, S. L,, and Huiatt, T. W. (1991). Use of a 
stable isotope methodology for studying the effects of leupeptin, calpain inhibitor I, and 
calpain inhibitor II on protein turnover in embryonic chick skeletal muscle cell cultures, 
(submitted) 
21. Mawhinney, T. P., Robinett, R. S., Atalay, A., and Madson, M. A. (1986). Analysis 
of amino acids as their rerf-butyldimethylsilyl derivatives by gas-liquid chromatography and 
mass spectrometry. J. Chromatogr. 358:231-242 
22. Tischler, M. E., Desautels, M., and Goldberg, A. L. (1982). Does leucine, leucyl-
TRNA, or some metabolite of leucine regulate protein synthesis and degradation in skeletal 
and cardiac muscle?. J. Biol. Chem. 257:1613-1621 
88 
23. Scomik, O. A., Lee, M., Ledbetter, S., and Malter, J. S. (1980). Role of 
aminoacylation of histidyl-t-RNA in the regulation of protein degradation in Chinese hamster 
ovary cells. J. Biol. Chem. 255:6322-6329 
24. Knowles, S. E., and Ballard, F. J. (1976). Selective control of the degradation of 
normal and aberrant proteins in reuber H3S hepatoma cells. Biochem. J. 156:609-617 
89 
SECTION m. DISPARATE RESPONSES OF CULTURED SKELETAL 
MUSCLE CELLS AND GROWING CHICKS TO 
TRIPEPTIDE ALDEHYDE PROTEASE INHIBITORS 
AND AN IN VIVO INTERACTION WITH 
ETHANOL 
90 
Disparate responses of cultured skeletal muscle cells and growing chicks to tripeptide 
aldehyde protease inhibitors and an in vivo interaction with ethanol. 
John C. Fuller, Jr.\ Greg A. Link\ Ted W. Huiatt^'^, Jerry L. Sell\ and Steve L. Nissen^ 
From the Departments of Animal Science^ and Biochemistry and Biophysics^, Iowa State 
University, Ames, lA 50011. 
Journal Paper No. J-14455 of the Iowa Agriculture and Home Economics Experiment 
Station, Ames, Iowa. Projects No. 2126, 2127, and 2887. This research received grant 
support from Iowa State University Biotechnology Council. 
Tripeptide aldehyde inhibitors in vivo and in vitro. 
Address correspondence to: Dr. Ted W. Huiatt, Muscle Biology Group, Iowa State 
University, Ames, Iowa 50011. 
Key words: muscle proteolysis, inhibitors, chicks, muscle cell culture. 
91 
ABSTRACT 
The objective of this study was to determine the effects of leupeptin and two leupeptin 
analogs (calpain inhibitors I and II) on protein turnover in embryonic chick skeletal muscle 
cell cultures and on growth of chicks. For in vitro studies, inhibitors (70 fcg/ml) were added 
to the medium of cell cultures for 24 h and proteolysis was determined by measuring the 
release of natural leucine into medium containing all leucine as 5,5,5-^H^-leucine. 
Compared with controls, leupeptin and calpain inhibitors I and n decreased proteolysis 
17.0%, 55.4%, and 60.6%, respectively. For in vivo studies, 7-day-old male White 
Leghorn chicks were given the inhibitors by daily intraperitoneal injection for 7 days. In 
experiment 1, inhibitors were administered in a 25% ethanol/75% saline carrier at doses of 
2.0 or 20.0 mg/kg body weight. Calpain Inhibitors I and II had no effect on lean tissue gain 
or feed efficiency. Leupeptin-injected chicks gained 51.1 ±2.1 g and control chicks gained 
43.2±2.1 g (P<0.05). In experiment 2, leupeptin was tested at four levels, and in addition, 
a group was injected with saline only. All chicks injected with ethanol/saline grew more 
slowly (P<0.05) than the saline-injected chicks, indicating that the ethanol suppressed 
growth. Leupeptin increased growth over that of ethanol/saline injected control chicks 
(P<0.05) at levels of 0.2, 2, and 20 mg/kg body weight. In experiment 3, leupeptin 
injected in a saline carrier was shown not to affect chick growth. These data demonstrated 
that, although calpain inhibitors were both 3-fold more potent than leupeptin in decreasing 
proteolysis in vitro, they did not alter in vivo growth of chicks. Only leupeptin improved 
growth in vivo and, then, only in chicks with growth suppressed by ethanol injection. 
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Whether leupeptin directly affects growth or indirectly alters growth through feed intake is 
unknown. 
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INTRODUCTION 
The protease inhibitor leupeptin has been shown to decrease protein breakdown in 
skeletal muscle cell cultures from both normal and dystrophic chick lines^'^. Riebow and 
Young^ suggested that soluble rather than myofibrillar protein turnover was inhibited. 
Leupeptin has also been shown to prevent or delay the effects of muscular dystrophy^'^, 
denervation atrophy^, long bone fracture'^, and elevated levels of glucocorticoids^ in vivo. 
However, in normally growing rats, leupeptin did not alter growth or protein 
turnover®'^' ^ ^ 
Structural modification of leupeptin may alter enzyme specificity as well as cell 
permeability such that potency would be enhanced. Leupeptin is a tripeptide aldehyde with 
the structure N-acetyl-leucyl-leucyl-arginal^^'^'*. The aldehyde functional group on the 
C-terminus is key to the inhibitor's activity^^, because it acts by forming a covalent 
hemiacetal or thioacetal adduct in the active site of serine and thiol proteases, 
respectively^^'^®. Leupeptin is a broad-based inhibitor that inhibits a variety of proteases: 
plasmin, trypsin, kallikrein, thrombokinase, papain^^, cathepsin and the 
calpains^®'^^. Two analogs of leupeptin have been chemically synthesized, and these are 
thought to be specific and potent inhibitors of the calcium activated neutral proteases 
(calpains)^®. These inhibitors, named calpain inhibitors I and II, have the structures N-
acetyl-leucyl-leucyl-norleucinal and N-acetyl-leucyl-leucyl-methioninal, respectively^®. They 
are 2-5 times more active than leupeptin in enzyme assays^®, but their effect has not been 
tested in cultured cells or animals. 
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The objective of this study was to determine the effects of leupeptin and its synthetic 
analogs, calpain inhibitors I and n, on protein turnover in embryonic chick skeletal muscle 
cell cultures and on growth of young chicks. The study was designed to demonstrate a 
decrease in protein breakdown in vitro with protease inhibitors and further characterize the 
potential growth response that might result in vivo. A second objective was to determine 
the relative in vivo effects of inhibitor treatment on carcass composition. 
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MATERIALS AND METHODS 
In Vitro Cell Culture Methods: 
Primary embryonic chick skeletal myotube cultures from 12-day White Leghorn type 
chick embryos were used for in vitro testing of inhibitor activity. Myoblasts from leg and 
thigh muscles were removed and plated on 60-mm collagen-coated plates (5.5 X 10^ 
cells/plate) as described by Ridpath et al^^ Cultures were grown for 7 days in 3 ml per 
plate of Dulbecco's MEM (DMEM deficient, low glucose, powdered, Sigma Chemical Co., 
St. Louis, MO) supplemented to contain all 20 amino acids, 10% pretested horse serum 
(Grand Island Biologies Co., Grand Island, NY), 2.5% embryo extract, 50 lU penicillin 
G/lOO ml (Gibco), and 1% Fungizone (Sigma). Cultures were grown in a 5% CO2 
atmosphere at 37*C and 90% humidity, and the culture medium was changed every 24 h. 
On days 5 and 6, medium containing 5 X 10"^ M cytosine-j3-D-arabinofuranoside was fed 
to kill any dividing cells and leave a relatively pure culture of fused, nondividing 
myotubes.^^ On day 8, cultures were rinsed once with phosphate buffered saline (3.3 mM 
NaH2P04, 6.7 mM Na2HP04, and 150 mM NaCl, pH 7.0), and fresh medium was added 
containing the protease inhibitors and in which all of the leucine was replaced by [5,5,5]-
^Hg-leucine (Tracer Technologies, Newton, MA). Leupeptin was obtained from Bachem 
Inc. (Torrence, CA). Calpain inhibitors I and II were obtained from Boehringer Manheim 
(Indianapolis, IN). All inhibitors were solubilized in 95% ethanol, and the resulting solution 
was diluted with water to yield a 25% ethanol stock solution containing 1.34 mg 
inhibitor/ml. Ethanol was used to solubilize all the inhibitors, because the calpain inhibitors 
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were insoluble in culture medium alone. Treatments were applied to cultures at 0.75 ml 
stock/10 ml medium, resulting in a final concentration of 70 ftg/ml of inhibitor and 1.875 
% ethanol in the culture medium. The control plates received the same ethanol mixture 
without inhibitors. During the next 24 h, natural leucine release into the medium was 
measured as an indication of relative proteolysis. Samples of 20 /tl of media were taken at 
1, 8, and 24 h and dried at 70*C under nitrogen gas. Samples were then derivatized with 
100 ^1 acetylnitrile plus 100 fd N-methyl-N-(t-butyl-chlorosilane)-trifluoroacetamide 
containing 1% t-butyldimethyl-chlorosilane (Regis Chemical Company, Morton Grove, 
IL)^. Natural and [5,5,5]-^H3-leucine were measured at 302 and 305 AMU, respectively, 
by using a gas chromatography-mass spectrometry system (Hewlett-Packard 5970A). 
Animal Experimental Metliods: 
Animals and diets. Three separate studies were conducted using 7-day-old male White 
Leghorn chicks. White Leghorns were chosen in preference to broilers because the genetic 
potential for protein growth in the Leghorn breed has been shown to be less than 
maximal^'^. Thus, a stimulatory effect on growth by protease inhibitors would be more 
likely to be observed in Leghorns than in broilers. 
In each study a pen of five chicks was used as the experimental unit. Allocation of 
experimental units to treatments was a completely randomized design. In the first 
experiment, in which all the inhibitors were tested, each treatment mean was the average of 
three pens per treatment. In the second experiment, in which leupeptin was injected in an 
ethanol solution, each treatment mean was the average of four pens per treatment. In the 
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third experiment, in which leupeptin was injected in normal physiological saline, each 
treatment mean was the average of six pens. Day-old chicks were obtained at hatching from 
Hyline (Dallas Center, lA) and grown for 7 days before allocation to treatments. 
Experimental units were selected from the pretreatment group for uniformity among the 
units. Chicks were kept in thermostatically controlled, electrically heated batteries. Feed 
and water consumption was free choice, and lights were on 24 h per day. The composition 
of the diet fed during both the pretreatment and treatment periods is shown in Table 1. 
Crude protein was increased 11 % above the requirement^ so that protein in the diet was 
not a limiting factor. 
Treatments. In experiments 1 and 2, inhibitors were prepared for injection by 
dissolving each inhibitor in 95 % ethanol and diluting to a final concentration of 25 % ethanol 
with sterile normal physiological saline. Final inhibitor concentrations injected were 0.6 and 
6 mg/ml for experiment 1 and 0.06, 0.3, 0.6, and 6 mg/ml in experiment 2. Ethanol was 
used in the carrier because Calpain inhibitors I and n were insoluble in saline alone. 
Calpain inhibitor I was marginally soluble in 95 % ethanol, but insoluble in 25 % ethanol/75 % 
saline and was, therefore, injected as a suspension. In experiment 3, leupeptin was dissolved 
in normal saline. All soluble inhibitor solutions were filtered by using a 0.22-/tm syringe 
filter. In all the experiments, the inhibitors were administered daily by intraperitoneal 
injection for 7 days. Dose was increased with the weight gain of the chicks such that total 
dose/body weight remained constant. The following dose schedule was used: day 1 and 2 
(200 Ml/day); day 3 and 4 (300 /tl/day); day 5, 6, and 7 (400 /tl/day). 
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Table 1 Composition of basal chick diets (percent of total mix, as fed). 
INGREDIENT PERCENT 
Com, grain 59.29 
Soybean meal (solvent ext) 19.72 
Wheat middlings 13.35 
Fish meal 3.00 
Dicalcium Phosphate 0.38 
Limestone 0.66 
Vitamin Premix^ 0.30 
Mineral Premix^ 0.30 
Meat and bone meal 3.(X) 
Nutrient Analysis (as-fed^ 
Metabolizable Energy (kcal/kg) 2900.00 
Crude Protein (%) 20.00 
^Supplied the following per kilogram of diet: 5,000 lU vit A; 
1500 lU vit D3; 25 lU vit E; 4.7 mg riboflavin; 21.5 mg pantothenic 
acid; 110 mg niacin; and 1649 mg choline. 
^Supplied the following per kilogram of diet: 83 mg zinc; 13.6 mg copper; 
101 mg manganese; 571 mg iron; 0.29 mg selenium; 1.7 g sodium; and 
2.5 g chloride, synthesis would not be limited by availability of 
dietary amino acids. 
Measurements. Each pen of birds was weighed daily. Feed intake was recorded for 
the 7-day treatment period. Carcass composition was determined from entire chick 
homogenates by previously described methods^®. At day 0, two groups of two chicks each 
were selected from the pretreatment chicks for basal composition, and at day 7, two chicks 
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nearest the pen mean were selected from each pen to determine posttreatment composition. 
Homogenates of the combined chicks from each pen were made and analyzed for percentage 
dry matter, crude protein, ether extract, and ash. Dry matter of the carcass sample was 
determined by drying in an air-convection oven for 48 h. Protein content of the dried 
samples was determined by the macro-Kjeldahl procedure (AOAC, 39.981.10)^^. Fat was 
determined by Goldfisch extraction of the dried samples (AOAC, 7.056).^^ Ash content 
of the dried samples was measured by heating at 600'C for 24 h (AOAC, 7.009).^® Net 
protein utilization (NPU) was calculated as protein gain/protein intake. The pectoralis major 
and minor muscles, liver, heart, and small intestine were dissected Arom two additional 
chicks from each pen and weighed. 
Statistics: 
Differences between treatments were assessed by using analysis of variance with the 
General Linear Models procedure of SAS (SAS Institute Inc., Cary, NC). The mathematical 
model for the animal experiments was Y;j= + Ey, where Yy, /*, Tj, and Ey were 
the observation, the population mean, the response to treatment effect, and the error term, 
respectively. Statistics were performed on pen averages and then expressed as per chick 
average in the tables. Cell culture data were from three plates per treatment and two 
replicate experiments were conducted for each calpain inhibitor in which control, leupeptin 
and a calpain inhibitor were used. For cell culture data an extra term was added in the 
model to remove week to week variation, Yyij= ft + jSTj + aWj + Ey^^, where Wj is the 
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component of week to week variation. Individual treatment means were compared by using 
the Duncan's multiple range test for means. 
101 
RESULTS 
Cell culture: 
The in vitro effects of leupeptin and calpain inhibitors I and II on skeletal muscle 
protein breakdown are shown in Table 2. Treatment of muscle cell cultures with protease 
inhibitors resulted in significantly less proteolysis as measured by natural leucine released 
into the medium over a 24 h period. Leupeptin inhibited proteolysis by 17% relative to 
controls. Calpain inhibitors I and II depressed proteolysis by 55 and 61%, respectively. 
Thus, calpain inhibitors I and 11 were 3-fold more potent than leupeptin in decreasing muscle 
protein breakdown in vitro. 
In vivo experiment 1, effects of leupeptin and analogs administered in 25% ethanol/75% 
saline: 
The body weight gain, gain of carcass components, feed intake, and feed efficiency 
per chick in experiment 1 are shown in Table 3. Treatments consisted of leupeptin, calpain 
inhibitors I and n, and a carrier-injected control. Inhibitors were administered at two levels, 
2.0 or 20.0 mg/kg body weight. Leupeptin treatment at both levels resulted in a significant 
increase in body weight gain relative to controls (P<0.05). Leupeptin-treated chicks also 
showed a trend toward increased dry matter and protein gain over controls, although the 
means were not significantly different. Calpain inhibitor II treatment also improved the gain 
of the chicks, but this difference was not significant and was due to increased water retention 
in this group in that dry-matter gain was not increased. When the body weights were 
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Table 2 In vitro effects of leupeptin and calpain inhibitors I and II 
on primary chick skeletal muscle cell cultures. 
% of the leucine in the medium as natural leucine (mean±sem). 
% Decrease^ 
Treatment 1 h 8 h 24 h 1-24 h 
Control 12 10.6±0.24 19.0±0.66 30.7±0.91 
Leupeptin 12 10.4±0.22 16.8±0.34 27.1 ±0.93 17.0^ 
Calpain Inhibitor I 6 10.5±0.38 13.5±0.38 18.1±1.59 55.4^ 
Calpain Inhibitor II 6 10.2 ±0.45 13.2±0.45 19.5 ±0.45 60.6^ 
^Relative to the control group for each set of experiments. Each experiment 
consisted of 3 control, 3 leupeptin, and 3 calpain inhibitor-treated plates. 
Percent decrease is the difference in release between the inhibitor-treated 
plates and the control plates for natural leucine released. 
^Data shown are the average of three plates per treatment and four duplicate 
experiments for leupeptin and two duplicate experiments for the calpain 
inhibitors. 
^All treatments resulted in significant decreases compared with controls 
as determined by Duncan's multiple range test for means (P<0.01). 
adjusted for differences in feed intake, calpain inhibitor I treatment resulted in lower body 
weight gains than the 2 mg leupeptin/kg body weight-treated chicks. All other differences 
were eliminated by the adjustment. No differences were observed in any of the tissue 
weights. Pooled means (±SEM) of the weights for liver and small intestine of all treatments 
were, as a percentage of body weight, 3.62±0.247 and 9.70±0.451, respectively. 
Pectoralis major and minor data are shown in Table 3. 
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Table 3 In vivo experiment 1, effects of leupeptin and calpain inhibitors I and n 
administered in 25% ethanol/75% saline. 
Treatment^ 
Control^ Leupeptin Calpain Inhibitor I Calpain Inhibitor II 
Dose 
(mg/kg body weight) (0) (2) (20) (2) (20) (2) (20) SEM^ 
Body weight gain (g) 43.2*'° 50.7® 51.1® 41.8": 39.0'= 44.8®'"= 49.6®'' 2.09 
Adjusted gain (g)'^ 45.6®'' 48.3® 47.0®'' 43.5'' 43.1'' 44.6®'' 48.0® 1.20 
Feed intake (g) 92.6'"= 101.2®'' 104.1® 93.8®'"= 89.6= 97.3®'"= 99.8®'"= 3.08 
Feed/gain 2.15®'' 2.00'' 2.04'' 2.25® 2.31® 2.18®'' 2.01'' 0.056 
Net protein utilization 0.41®^ 0.42®'' 0.43® 0.39®'' 0.39®'' 0.39®'' 0.35'' 0.023 
Dry-matter gain (g) 12.90 13.61 14.83 12.36 12.13 13.11 12.11 1.132 
Protein gain (g) 7.68 8.64 8.96 7.45 7.06 7.69 7.04 0.615. 
Fat gain (g) 4.36 3.81 4.98 3.70 3.78 4.43 3.87 0.666 
Ash gain (g) 1.25®'' 1.27®'' 1.43® 1.23®'' 1.21'' 1.21'' 0.98= 0.065 
Pectoralis major 
(% body wt) 3.27 3.35 3.27 3.09 2.90 3.34 3.25 0.107 
Pectoralis minor 
(% body wt) 0.77 0.80 0.71 0.69 0.72 0.74 0.69 0.(W9 
^Data shown are the average of three pens per treatment expressed on a per chick basis. 
Superscripts without a common letter indicate significant differences (P<O.OS) as indicated 
by Duncan's multiple range test for means. No differences exist where there is no 
superscripting. 
^Controls received the 25% ethanol/75% saline carrier without inhibitor by daily 
interperitoneal injection for seven days. 
^Pooled standard error of the mean. 
'^Body weight gains adjusted for feed intake. 
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In vivo experiment 2, dose response of leupeptin administered in 25% ethanoI/75% 
saline: 
Because leupeptin was the only inhibitor that improved growth in vivo, a dose 
response for leupeptin was investigated in experiment 2. A saline-injected control group was 
also included to determine if the ethanol in the carrier had any effect on the growth of the 
chicks. 
Table 4 depicts the body weight gain, carcass gain, and feed efficiency per chick at 
treatment levels of 0, 0.2, 1.0, 2.0, and 20.0 mg/kg body weight leupeptin. In agreement 
with the data from experiment 1, leupeptin-treated chicks were significantly heavier than the 
ethanol/saline-treated control chicks at every level tested except 1.0 mg/kg (P<0.05). As 
in experiment 1, adjustment for differences in feed intake eliminated most all of the 
differences in body weight gain. After adjustment, the only significant (P < 0.05) difference 
was between the 1 mg leupeptin/kg body weight and saline-treated chicks. The gains of the 
leupeptin-treated chicks at the 0.2,2, and 20 mg/kg levels were numerically lower than those 
of saline-treated chicks, but they were not significantly different given the experimental 
variation. This difference was also reflected in the carcass component gains, relative to the 
ethanol/saline control group inasmuch as dry-matter, protein, and ash gains were all 
improved with leupeptin treatment, though these differences were for the most part not 
significantly different from the control groups. Composition of the gain was unchanged by 
treatment. However, the ethanol/saline-treated control chicks exhibited about 30% growth 
depression relative to the 100% saline-treated control chicks. Leupeptin, however, partly 
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Table 4 In vivo experiment 2, dose response of leupeptin administered in 25 % ethanol/75 % 
saline. 
Treatment^ 
Control^ Leupeptin 
Saline Ethanol 
Dose 
(mg/kg body weight) (0) (0) (0.2) (1) (2) (20) SEM^ 
Body weight gain (g) 62.3= 42.2= 53.3"^ 50.0''® 52.7®'' 54.5®'' 3.17 
Adjusted gain (g)'^ 54.8® 51.7®'' 53.2®'' 49.6'' 53.8® 51.7®'' 2.80 
Feed intake (g) 119.0® 93.7'' 108.0® 108.4® 106.1®'' 112.1® 4.38 
Feed/gain 1.91® 2.26® 2.03''® 2.19®'' 2.02''® 2.06®''® 0.071 
Dry-matter gain (g) 17.97® 11.78'' 14.87®'' 14.66®'' 16.74® 16.13® 1.067 
Protein gain (g) 11.11® 7.59'' 9.28®'' 9.30®'' 9.76®'' 9.77®'' 0.679 
Fat gain (g) 4.29 2.33 2.92 3.41 4.32 3.85 0.604 
Ash gain (g) 1.47® l.Ol'' 1.36®'' 1.25®'' 1.40® 1.35®'' 0.115 
Net protein utilization 0.46 0.40 0.43 0.42 0.45 0.43 0.021 
Pectoralis major 
(% body wt) 3.26 3.47 3.11 2.92 3.27 3.19 0.154 
Pectoralis minor 
(% body wt) 0.88 0.92 0.79 0.83 0.86 0.79 0.044 
^Data shown are the average of four pens per treatment expressed on a per chick basis. 
Superscripts without a common letter indicate significant differences (P<0.05) as 
indicated by Duncan's multiple range test for means. No differences exist where there is 
no superscripting. 
%thanol controls received the 25% ethanol/75 % saline carrier without inhibitor and saline 
controls received saline alone administered daily by interperitoneal injection for 7 days. 
^Pooled standard error of the mean. 
'^Body weight gdns adjusted for feed intake. 
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blocked this response to the ethanol, inasmuch as the gains of the leupeptin-treated chicks 
were intermediate between the ethanol/saline and 100% saline-treated control chicks. No 
significant differences were observed in organ weights. Pooled means (±SEM) of all 
treatments obtained for heart, liver, and intestine, as a percentage of body weight, were 
0.74±0.041,2.97±0.117, and 8.99±0.441, respectively. Pectoralis major and minor data 
are shown in Table 4. 
In vivo experiment 3, dose response of leupeptin administered in saline: 
A third experiment was conducted to test the effects of leupeptin injected in a saline 
carrier because, unlike the calpain inhibitors, leupeptin was soluble in saline. Body weight 
gain and feed efficiency per chick are shown in Table 5. Dosage levels of leupeptin were 
the same as in experiment 2: 0, 0.2, 1.0, 2.0, and 20.0 mg/kg body weight. In contrast to 
the data from experiments using ethanol/saline as a carrier, no differences were observed in 
gain, feed efficiency, or organ weights, other than the pectoralis major, of chicks when 
leupeptin was injected in a normal saline carrier. Pooled means (±SEM) of all treatments 
for heart, liver, and intestine weights expressed as a percentage of body weight were 
0.82±0.036,3.20±0.133, and 7.37±0.229, respectively. Pectoralis major and minor data 
are shown in Table 5. Even though there was a significant difference (P < 0.05) in pectoralis 
major weights expressed as a percentage of body weight, the difference was not meaningful 
to the interpretation of the results and probably was due to random experimental error, such 
as an error in dissection. Carcass composition was not determined in this experiment. 
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Table 5 In vivo experiment 3, dose response of leupeptin administered in saline. 
Treatment^ 
Control Leupeptin 
Dose (0) (0.2) (1) (2) (20) SEM^ 
(mg/kg body weight) 
Body weight gain (g) 
Feed/gain 
Pectoralis major 
(% body wt) 
Pectoralis minor 
(% body wt) 
0.5 58.5 59.6 
2.01 2.00 2.03 
3.45^ 3.13'' 3.44^ 
0.85 0.81 0.88 
60.1 59.5 2.92 
2.01 2.04 0.225 
3.30^^ 3.33^^ 0.074 
0.86 0.85 0.035 
^Data shown are the average of six pens per treatment expressed on a per chick basis. 
Superscripts without a common letter indicate significant differences (P<0.05) as 
indicated by Duncan's multiple range test for means. No differences exist where there is 
no superscripting. 
^Pooled standard error of the mean. 
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DISCUSSION 
Leupeptin inhibited proteolysis in primary skeletal muscle cell cultures by 17% 
relative to controls. Analogs of leupeptin (calpain inhibitors I and II) inhibited proteolysis 
by up to 61% in vitro. This is consistent with previous work on isolated calpain proteases 
with these inhibitors when inhibitor:protease interactions were studied in vitro^®. These 
results suggest that changing the C-terminal amino acid aldehyde residue of leupeptin can 
increase potency of the inhibitor by 3-fold in skeletal muscle. It remains to be shown if this 
effect is specific to myofibrillar protein turnover and if similar effects can be demonstrated 
in cell types other than skeletal muscle. 
Chicks treated with calpain inhibitors I and II showed no improvement in lean tissue 
growth. Chicks treated with calpain inhibitor n did show a gain response at the high dose 
level, but this was primarily due to an increase in water retention rather than an increase in 
lean-tissue mass. This is in contrast to effects observed in cell cultures. One factor that may 
contribute to the difference between leupeptin and the calpain inhibitors in vivo is the 
insolubility of the calpain inhibitors in both normal saline and cell culture media. Despite 
insolubility, the calpain inhibitors still decreased protein breakdown in vitro, suggesting that 
some inhibitor penetrated the cell to inhibit proteolysis. In chicks, no obvious signs of 
inhibitor precipitation or tissue abnormalities at the sight of injection were observed after 
treatment. Thus, inhibitors evidently were absorbed through the peritoneal cavity. When 
considering possible in vivo differences, such as, tissue distribution, effective cellular 
concentration, and mode of cell penetration of these inhibitors, great differences may exist 
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between in vitro and in vivo systems. Clark and Williams^^ have suggested that leupeptin 
may enter the cell by pinocytotic and nonpinocytotic routes, but the mode of penetration of 
the calpain inhibitors remains to be described. 
Leupeptin did improve body weight gain, carcass protein gain, and feed efficiency 
of chicks when administered in a ethanol/saline carrier regardless of the dose tested. 
Leupeptin's effects, however, were restricted to chicks injected with the ethanol/saline 
carrier, which were growing at less than maximal rates. In vivo experiments showed that 
the 25% ethanol/75% saline carrier depressed growth by 30-35%. Gain and feed intake 
were highly correlated (P<0.01), which is to be expected. In experiments 1 and 2, if body 
weight gains are equalized for feed intake, then no significant difference in gain was seen. 
The ethanol-induced growth depression may result from decreased feed intake and leupeptin 
may be affecting feed intake positively, thus overcoming the intake-induced growth 
depression. Further studies with pair-fed chicks would be necessary to determine if leupeptin 
was affecting catabolic metabolism or changing the feed intake of the chicks. Gain and feed 
efficiency were unchanged by leupeptin when saline, rather than ethanol/saline, was used as 
a carrier. This is consistent with previous work in rats, which showed no effect of leupeptin 
on normal growth®'^^. 
Organ weights, as a percentage of body weight, in all studies were unchanged by 
leupeptin. Thus, it seems that the gain response to leupeptin was not organ specific. 
Carcass composition was also unchanged by leupeptin in these young chicks. Therefore, 
protease inhibitors seemed not to display a nutrient partitioning effect in vivo. 
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In summary, altering the structure of leupeptin can enhance potency in inhibiting 
proteolysis in skeletal muscle cells in culture, but these changes in protein metabolism in 
vitro do not necessarily translate to changes in growth in vivo. Factors such as tissue 
distribution, cellular-level concentrations, and mode of cell penetration may explain this 
disparity. In vivo, leupeptin improves protein balance in abnormally high catabolic states, 
but it has little or no effect on normal growth and protein accretion. 
I l l  
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GENERAL SUMMARY AND CONCLUSIONS 
The overall objectives of my work were: (1) To develop a stable isotope labelling 
protocol that would be sensitive enough to detect small differences in relative protein 
degradation in embryonic chick skeletal muscle cell cultures; (2) To use this methodology 
to examine the effects of added compounds on protein degradation; and (3) When compounds 
affecting protein degradation were identified in vitro, to conduct an in vivo study to 
determine if these effects would also be evident in growing chicks. These series of 
experiments were done to achieve these objectives. 
The first set of experiments, described in section I, described the method for use of 
stable isotope labelling of cell culture proteins to study protein degradation. Stable isotope 
measurement of proteolysis in cell cultures offers a simple one step analysis of the culture 
medium for the specific compound of interest. The effects of leupeptin and the calpain 
inhibitors I and II on protein degradation were examined. The optimal labelling was found 
to be to look at natural leucine release into medium containing a stable isotope of leucine. 
The response of primary chick embryonic skeletal muscle cell cultures to the calpain 
inhibitors I and II was also presented. The effects of leupeptin were examined and this 
resulted in 13 % inhibition of protein degradation with a 24 h radiolabel and 24 % inhibition 
with a 7 d stable isotope label. These results are in agreement with the reported leupeptin 
results. The 7 d label would be incorporated to a higher specific activity in many long half-
life proteins in the cell and tiius, was probably a better indication of the effects of leupeptin 
on general protein degradation than the results of shorter labelling protocols. Therefore, it 
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is not surprising to see a greater response with the longer labelling method. In fact, the 
longer the labelling period attainable, probably the truer the value obtained will be to 
representing general protein turnover. The stable isotope labelling protocols consistently 
showed more consistent and earlier differences among the various inhibitor treatments than 
did the radioisotopes. 
The second set of experiments examined the effects of cycloheximide on protein 
degradation using the stable isotope methodology. These experiments were done because 
cycloheximide is commonly used to block protein synthesis during studies of protein 
degradation, thus eliminating reutilization of the label. The difference observed was not 
expected as cycloheximide is commonly used to block reutilization of label so the absolute 
rate of protein degradation, which should be greater than without cycloheximide, can be 
obtained. We found that cycloheximide decreased protein degradation. From 1 to 8 h post 
treatment with cycloheximide protein degradation was decreased by 27 and 18 % with the 
short- and long-term labels, respectively, when compared with label released from the 
control cultures. At 24 h protein degradation in the cultures had been depressed 48 % for 
both labels relative to the controls. 
The last experiments conducted compared the in vitro inhibitor results to those 
obtained in vivo with growing chicks. Despite a large increase in effect over leupeptin in 
vitro, in vivo the calpain inhibitors, as tested, had no significant effect on chick growth. 
Leupeptin did positively effect chick growth when administered in a 25 % ethanol solution, 
however, when administered in normal physiological saline leupeptin had no effect on the 
growth of the chicks. Thus, leupeptin positively effects the growth of chicks in an ethanol 
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induced higher than normal catabolic state, but not of chicks growing normally. This agrees 
with other reports that leupeptin effects are only seen in abnormal catabolic states and after 
The overall conclusions of these studies are: 
1) That stable isotope labelling of protein for protein degradation studies is probably 
a much more accurate indicator of differences than typical radioisotope labelling. 
Higher specifîc activity of label in the protein is attainable with the stable isotope 
methodology. With this method it was shown that the calpain inhibitors I and n 
decreased proteolysis by up to 60 % in embryonic chick skeletal muscle cell cultures. 
2) Cycloheximide's effect on protein degradation invalidates its use to study absolute 
rates of proteolysis and may in fact mask treatment effects on protein degradation. 
3) In vitro results with the inhibitors did not translate into in vivo effects, in that o 
effect of either leupeptin or calpain inhibitors was seen in normally growing chicks. 
Further work is necessary before any practical application of direct proteinase 
inhibition might be applied to meat animal growth, however, proteinase inhibitor treatment 
in certain disease conditions may be of importance sooner. Proteinase inhibitors, as well as 
identification and modification of proteinase genes, will probably play increasingly important 
roles in the identification of basic proteolytic mechanisms. Central to the understanding will 
be the importance of being able to make accurate measurements in the changes in proteolysis 
that occur as portions of the mechanisms are elucidated. 
Two other sets of experiments have been conducted as a part of this work, but are 
not reported here. First, amino acid analogs were included in culture medium and the effect 
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of abnormal proteins on protein degradation was examined using the methodologies presented 
in section I. Secondly, validation of a carboxyl oxygen labelled leucine for use as a tracer 
in protein turnover was undertaken. Manuscripts will be prepared soon from both of these 
series of experiments. 
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